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ABSTRACT
The field of salvinorin chemistry represents a novel and emerging field of opioid
research. The novelty is derived from the lead pharmacophore: salvinorin A — a neoclerodane
diterpenoid natural product isolated from Salvia divinorum. Salvinorin A represents a
pharmacologically unique compound in that it is the first known non-nitrogenous KOR subtypeselective agonist, exhibits a comparatively safe physiological profile with no reports of
toxicological effects in clinical trials, and, most importantly, has a steadily growing body of
literature indicating potentially useful clinical applications (e.g. antinociceptive, anti-addictive,
antipruritic, neuroprotective, etc.). This has encouraged the development of analogues as
essential molecular probes to elucidate the structure-activity-relationship of the salvinorin-class.
In this study, we expand the current field of salvinorin chemistry through the design,
development, and preclinical evaluation of a series of C(22)-fused heteroaromatic salvinorin A
analogues. Our in vitro models include: opioid receptor competitive radioligand binding affinity
and functional [35S]GTP[γS] binding activity assays; while our in vivo models include:
antinociceptive, antidepressant, and anxiolytic related assays. This resulted in three analogues
exhibiting EC50 sub-200 nM functional activity, of which two displayed antinociceptive
activities, with one also demonstrating antidepressant-like activity. As such, this study further
supports the importance of the continued development of new salvinorin A analogues as
essential research tools to ascertain potential three-dimensional ligand binding requirements,
functional activities, and pharmacological consequences mediated through the clinically
important opioid receptors.
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CHAPTER 1: Salvia divinorum
In 1939 anthropologist Jean Bassett Johnson reported the use of hallucinogenic
mushrooms by the Mazatec in Mexico, as well as, the use of an infusion of leaves from a plant
called hierba María for similar purposes (Johnson, 1939). However, he was unable to secure a
suitable herbarium specimen to allow for botanical taxonomy to be established. It was not until
1962 that Robert Gordon Wasson, while exploring the Sierra Mazateca in Oaxaca Mexico and
studying the Mazatec use of hallucinogenic mushrooms, was able to both secure a suitable
herbarium specimen, as well as, substantiate the previously reported activity of prepared
infusions of the plant material by participating in its ceremonial use:

The effect of the leaves came sooner than would have been
the case with the mushrooms, was less sweeping, and lasted
a shorter time. There was not the slightest doubt about the effect,
but it did not go beyond the initial effect of the mushrooms –
dancing colors in elaborate, three-dimensional designs. Whether
a larger dose would have produced a greater effect, I do not know.
(Wasson, 1962)

Ritual preparation consists of pairing “flawless” leaves together, 50-100, and masticating
the leaves for effect. Alternatively, and the method used by Wasson, is to grind the leaves with
water, straining and consuming the resulting infusion for effect (Wasson, 1962). The

ceremonious use of this plant, described by both Wasson and earlier investigators such as
Blas Pablo Reko, indicate that the purpose is divinatory in nature (Reko, 1945 and Wasson,
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1962). A curandero would initiate the ritual to divine the cause of disease in participating
patients. It is the divinatory use of this plant and, especially, the use of infusions prepared
from its leaves that led Wasson to propose that Salvia divinorum may represent the ancient
Aztec plant pipiltzintzintli (Wasson, 1963). Beyond the use of this plant for divinatory purposes
it is also used medicinally by the Mazatecs to treat diarrhea, headaches, rheumatism and a
Mazatec illness known as panzón de barrego [sic] (swollen belly). Additionally, it is used in
patients that are near death to revive and alleviate them of their illness (Johnson, 1939 and
Valdés III et al., 1983).
The herbarium specimen obtained
by Wasson was provided to Carl Epling
and Carlos D. Játiva-M. who identified it as
an undescribed species in the Lamiaceae
family designating the new species as
Salvia divinorum (Epling and Játiva-M.,
1962) (Figure 1, line drawing; Figures 2
and 3, photographs of cultivated specimen;
Figure 4, photograph of specimen in natural
habitat). Botanically this species is
characterized as a perennial herb averaging
approximately a meter in height. Mature
leaves are approximate 14 cm long (Figure

Figure 1. Salvia divinorum line drawing.
Adapted from Schultes and Hofmann, 1973.

5A), ovate, acuminate, basally rounded,
crenate-serrate with hairs in sinuses along the margins, glabrate but hirtellous along the lower

2

veins that attenuate into a petiole 2-3 cm long. The inflorescence is characterized by being
bluish, slightly pubescent, in full panicles on branches approximately 35 cm long, with a violet
calyx tube, approximately 15 mm long with superior lip 1.5 mm long and three impressed veins,
lip 6 mm tall, inferior lip shorter and incurved.

3

Figure 2. Photograph of cultivated Salvia divinorum plant illustrating general
growth habit.

4

Figure 3. Photograph of cultivated Salvia divinorum plant illustrating
characteristic square stem and oppositely decussate leafing pattern.

5

Figure 4. Photograph of Salvia divinorum plant in natural habitat that illustrates the toppling
growth pattern observed in this species.
[Creative Commons image: CC BY-SA 3.0,
https://commons.wikimedia.org/w/index.php?curid =157218]
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The corolla tube is white, sigmoid, 22 mm long, with superior lip 6 mm tall, inferior lip
shorter and incurved. The stamens are inserted near the mouth of the tube: style hirtellous, with
posterior branch long, obtuse, flat, anterior carinate branch (Epling and Játiva-M., 1962; Schultes
and Hofmann, 1973; Valdés III et al., 1987). Additionally, it was widely thought that this plant
may represent a cultivar as it was essentially unknown outside of curandero cultivated patches
isolated in the Sierra Mazateca highlands (Ott, 1993). However, this appears to be due to a
characteristically low seed-set and limited seed viability observed in this irregularly flowering
plant as seed-set was first demonstrated in 1987 (Valdés III et al., 1987). Laboratory cultivation
experiments revealed low pollen viability (approximately 56% failure) from pollinated stigmas
resulting in low seed-set (Jenks et al., 2011 and Reisfield, 1993).
A.

B.

Figure 5. [A] Photograph of Salvia divinorum leaf, fresh. [B] Photograph of
lyophilized Salvia divinorum leaf material coarsely ground prior to extraction.
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Salvia divinorum, while reported at several locations ranging from 500 to 1500 meters in
altitude, has a limited geographical distribution within the highlands of the Sierra Mazateca in
Oaxaca, Mexico (Figure 6) (Casselman et al., 2014 and Reisfield, 1993). This range is typified
by tropical montane cloud-forests (i.e. persistent cloud cover resulting in high humidity). As an
herbaceous plant Salvia divinorum represents an understory member whose populations are
generally in partial to full shade conditions in nutrient-rich, moist soils often found near water
courses. Either naturally, by toppling over (Figure 4), or aided by curanderos Salvia divinorum
is propagated primarily vegetatively through clonal growth.
The first live collection of Salvia divinorum that was successfully propagated outside of
Oaxaca was deposited by Sterling Bunnell at the University of California, Los Angeles Botanical
Garden in 1963 and consisted of a single specimen (Siebert, 2003). Due to the notable low seedset rate, usual method of clonal propagation, and limited number of reported live collections it is

Figure 6. Distribution of Salvia divinorum within the Mazatec territory. See
gray zone within inset region of Oaxaca. Adapted from Casselman et al., 2014.
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suggested that this plant is likely the progenitor of the vast majority of propagated Salvia
divinorum currently available outside of Oaxaca, Mexico. Intraspecific genetic studies of five
populations obtained from within Sierra Mazateca revealed a limited genetic diversity, as well
as, placed the species outside of the Salvia “core" subgenus Calosphace with Salvia venulosa
being supported as its closest related species by both ITS and cpDNA phylogenetic assessment
(Jenks et al., 2011). Additionally, the authors indicated that the species appear reproductively
capable but that anthropogenically-mediated clonal propagation may negatively affect this
capacity. However, they concluded that further studies are needed into the sexual reproductive
capacity and genetic diversity of the species.
Phytochemical investigation into the active constituents of Salvia divinorum began with
Albert Hofmann in 1964, due in part to his close association with Wasson, having accompanied
the 1962 expedition (Wasson, 1962). However, more important was Hofmann’s unparalleled
expertise with hallucinogenic compounds (Figure 7): having discovered lysergic acid
diethylamide (LSD; initial synthesis in 1938 and re-examination in 1943), and more relevantly,
his experience working with other Mazatecan hallucinogenic species from Mexico, including the
identification of psilocybin and psilocin as active constituents from the hallucinogenic
mushroom Psilocybe mexicana (subsequently, isolated from numerous Psilocybe species;
Nahuatl: teonanácatl) and the identification of lysergic acid amide as the active constituent from
Turbina corymbosa seeds (Nahuatl: ololiuhqui) (Hofmann, 1964).

9

Lysergic acid diethylamide

Lysergic acid amide

Psilocybin

Psilocin

Figure 7. Hallucinogenic alkaloids discovered by Hofmann.

This pattern of alkaloids consistently being the perceptiotropic constituent suggested that
a similar pattern may be observed with Salvia divinorum. Starting with an infusion prepared in
Mexico and preserved with alcohol Hofmann attempted, and failed, to isolate the causative
alkaloid upon return to his laboratory in Basel, Switzerland. When he reassessed the alcohol
preserved infusion via experimenter self-administration he discovered that the material was
inactive — concluding that the perceptiotropic principle was unstable in solution and that “the
problem of the magic plant ska María Pastora still awaits solution” (Hofmann, 1979).
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CHAPTER 2: Salvinorin A
Hofmann’s Solution
The solution to Hofmann’s Salvia divinorum problem continued to remain elusive until
1984 when Leander J. Valdes, III and collaborators utilized an in vivo bioassay-guided approach
toward fractioning lyophilized leaf material (Figure 5B) (Valdes, III, et al. 1984). Employing a
modified open field test (OFT), column fractions of the extracted leaf material were assessed at
each stage of silica gel chromatographic purification for altered activity in mice. This process
led to the isolation of a neo-clerodane diterpenoid which they designated as divinorin A. During
the publication process they learned that the compound, divinorin A, had been previously
reported by Alfredo Ortega in 1982
as salvinorin A (Ortega et al.,
1982). The Ortega group had
utilized a blind-fractionation
process to isolate salvinorin A
(Figure 8) and had not evaluated
the compound pharmacologically.
However, it wasn’t until
1994 that the first pharmacological
evaluation of salvinorin A in
humans was reported (Siebert,

Figure 8. Structure of salvinorin A.
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1994). In this study, Daniel J. Siebert, with six volunteers, assessed both traditional Salvia
divinorum leaf infusions (gastrointestinal absorption versus buccal absorption) and pure
salvinorin A (buccal absorption versus vaporized inhalation absorption). This study was
important as it was the first to verify the perceptiotropic effects of salvinorin A in humans.
Additionally, it served to establish the initial pharmacology of the compound in humans. Siebert
discovered that salvinorin A is an extremely potent perceptiotropic substance, which is active at
200-500 μg when vaporized and inhaled (they tested doses up to 2.6 mg with no adverse effects
observed).
Pharmacologically they established that vaporization/inhalation effects are markedly
different from the more traditional route of administration. The traditional route (i.e. buccal
absorption) results in perceptiotropic effects that are as described in the earlier literature: mild
hallucinogenic activity that takes approximately ten minutes before initial effects are felt, that
plateau for about one hour before gradually subsiding over the next hour. This contrasts sharply
when administered via vaporization and inhalation: the full effects are best described as
dissociatively hallucinogenic and is experienced in approximately thirty seconds and last for
five-to-ten minutes. In an attempt to establish the pharmacological target of salvinorin A Siebert
collaborated with David Nichols to screen at a series of likely neuroreceptors, such as the
dopamine and serotonergic receptors. However, they found no significant activity at any of the
screened receptors (Siebert, 1994).
It wasn’t until 2002 when Siebert collaborated with Bryan L. Roth of the National
Institute of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP) that a
pharmacological target was elucidated. Employing a competitive radioligand binding assay
against fifty cloned human G-protein-coupled receptors (GPCRs) they discovered, surprisingly,
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that salvinorin A not only bound to the opioid receptors, but was subtype selective, exhibiting
potent selectivity for the kappa opioid receptor (KOR) subtype (Figure 9). This was followed
with functional assessment utilizing a [35S] GTP[γS] assay at KOR that revealed salvinorin A
was a potent agonist with an EC50 of approximately 1 nM. This represents the first report of a
non-nitrogenous subtype-selective opioid receptor agonist (Roth et al.¸ 2002). It also represents
the solution to “the problem of the magic plant ska María Pastora” posed by Hofmann that was
forty years in the making and the beginnings of the field of salvinorin chemistry.

Figure 9. Screening of Salvinorin A in competitive radioligand binding assays
against fifty cloned human GPCRs at 10μM, demonstrating selectivity at hKOR.
LSD is shown as comparison. Roth et al. 2002. Reprinted with permission.
13

The Opioid System — A Clinically Important Target
The opioid system is crucially involved in the modulation of antinociception and
associated behaviors. Chronic pain affects an estimated 100 million Americans, has associated
costs exceeding $600 billion per year in lost productivity and medical expenses, and the
currently available drug therapies consist primarily of classical opioid analgesics such as
morphine and closely related analogues (Prisinzano, 2013). Compounding the issue, admissions
for treatment of prescription opioid abuse has increased by an astounding 400% over the past 15
years and the death rate (estimated by the CDC at 90 Americans per day in 2015) from opioid
drug use exceeds all other drug classes (Ling et al, 2011; Nielsen and Bruno, 2011; Rudd et al.,
2016). Beyond legal production it is estimated that annual production of illicit opioids exceeds
$800 billion (Rinner and Hudlicky, 2012). In spite of these problems, opioids continue to be the
most prescribed, and abused, class of drugs (Negri et al., 2013).
Extending beyond antinociception, numerous studies have indicated involvement of this
system in a diverse array of critical behavioral states, including: addiction, anxiety, and
depression — further reinforcing the clinical importance of this system (Al-Hasani and Bruchas,
2011; Lalanne et al., 2014; Ling et al., 2011). The opioid system is composed of four G-proteincoupled receptors (GPCRs) that belong to the Rhodopsin-like, Class A, subfamily that include
opioid receptors (OR): delta (DOR), kappa (KOR), mu (MOR), and nociception (NOR) — with
an increasing number pharmacologically defined subtypes for each resulting from alternative
splicing, post-translational modification, and/or receptor oligomerization (Al-Hasani and
Bruchas, 2011; Stein, 2016; Urbano et al., 2014; Ying-Xian et al., 2003).
The opioid receptors are widely expressed throughout both the peripheral and central
nervous systems, as well as throughout diverse systems such as: cardiovascular, gastrointestinal,
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and reproductive (Feng et al., 2012). Physiologically, DOR, KOR, and MOR are each
modulated by several endogenous neuropeptides that are subtype cognate (Table 1). For
example, DOR is activated by enkephalins (Figure 10), KOR by dynorphins (Figure 11) and
MOR by endorphins (Figure 12) — however, this is a preferential affinity as there is some
degree of non-selectivity exhibited by these representative endogenous ligands across the

Table 1. Representative Endogenous Opioid Peptides.
Primary
Target

Sequence
(Three-Letter-Code)

Peptide

DOR

Tyr-Gly-Gly-Phe-Met

[Met5]-encephalin

DOR

Tyr-Gly-Gly-Phe-Leu

[Leu5]-encephalin

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys

dynorphin A

KOR

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr

dynorphin B

KOR

Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-ThrArg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Tyr-Glu-Glu-LeuPhe-Asp-Val

leumorphin

MOR

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-LeuVal-Thr

α-endorphin

MOR

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-LeuVal-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-LysLys-Gly-Glu

β-endorphin

MOR

Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-LeuVal-Thr-Leu

γ-endorphin

MOR

Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys

α-neo-endorphin

MOR

Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro

β-neo-endorphin

NOR

Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-LysLeu-Ala-Asn-Gln

Nociceptin

KOR

Compiled from the following references: Hazum et al., 1979; Janecka et al., 2004; Kangawa
et al., 1981; Minamino et al., 1981; Nakao et al., 1983; Suda et al., 1984; Toll et al., 2016.
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subtypes (Albert-Vartanian et al., 2014; Phan et al., 2012).

The nociceptin opioid receptor

(NOR) represents an atypical opioid receptor in that it possesses limited pharmacological
response to classical opioids, despite assignment based on amino acid sequence homology, its
cognate endogenous peptide has been identified as a unique heptadecapeptide ligand designated
as nociceptin (Meunier et al., 1995).
Complications in clinically targeting opioid receptor subtypes, and their variants, arises
from the high degree of amino acid residue homology observed between DOR, KOR, MOR, and
NOR — with greater than 70% homology observed in the II, III, VII transmembrane (TM)
helices (TM2, TM3, TM7), 50% homology between I, V, VI (TM1, TM5, TM6), and 24%
homology within IV (TM4) (Toll et al., 2016). Despite this high degree of homology, the
receptor subtypes exhibit a range of pharmacological distinctiveness including desirable
properties such as analgesia and anxiolytic effects or undesirable properties such as anhedonia or
impaired coordination.

[Leu5]-enkephalin

[Met5]-enkephalin
Figure 10. Structures of representative encephalin-class endogenous opioid peptides.
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Dynorphin A

Dynorphin B

Figure 11. Structures of representative dynorphin-class endogenous opioid
peptides.
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α-endorphin

Figure 12. Structure of representative endorphin-class endogenous opioid peptide.
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Morphine Chemistry — Origins of Classical Opioids
It is the pursuit of these desirable drug-induced properties that has fostered research into
small molecule ligands targeting the opioid receptors and to a degree that far outdistances that of
current peptide research. This is, in large part, due to the rather lengthy history of
ethnomedicinal use of the plant Papaver somniferum — otherwise known as opium poppy.
Some of the earliest archaeological evidence indicating human cultivation of Papaver
somniferum dates back to approximately 5700 BCE from the site of an early European Neolithic
settlement discovered submerged under Lake Bracciano, Italy (Merlin 2003). Evidence of the
use of this plant continues during the Bronze Age (circa 1550-1100 BCE) with the discovery of
numerous poppy capsule artifacts (Figure 13) present throughout mainland Greece indicating a

Figure 13. Greek poppy capsule artifact. Merlin, 2003. Reprinted
with permission.
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likely significance beyond mere food substance and a connection with ritual and/or medicinal
use of the plant. This was later substantiated in the writings of Hippocrates of Kos during the
Classical Greece period (circa 500-400 BCE) (Kritikos and Papadaki, 1967). However, the first
written record of the medicinal use of Papaver somniferum was much earlier, being found in the
Ebers Papyrus from Egypt, written circa 1550 BCE, that indicated the use of this plant for
sedative effects (Atanasov et al., 2015).
Eventually this usage extended into analgesic effects by the Archaic Greece period
(circa 800-500 BCE) preceding the Classical Greece period and possibly noted in The Odyssey:

…she cast a drug into the wine of which they drank to lull
all pain and anger and bring forgetfulness of every sorrow.
(Homer, early 8th Century BCE)

The harvesting of the milky-white latex (Figure
14) (Greek opos ; opium) that is collected by
lancing unripe seed capsules of Papaver
somniferum which upon drying results in a
viscous, dark brown-black resinous material
that is raw opium (Figure 15) (the Greek
μηκώνιον; mekonion). However, it is likely
that analgesic use extends even further in
antiquity, as archeological evidence indicates
that as early as 3000 BCE the Sumerians

Figure 14. Lanced Papaver somniferum
seed pod exuding opium latex. [Public
Domain image from TeunSpaans, 2017]

referred to the opium poppy as “hul gil” — the
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plant of joy (Brownstein, 1993).
Additionally, during this time (circa 1300-1000 BCE) trade had seen the spread of
Papaver somniferum, as both a food and medicinal substance, from the Asia Minor and
Mediterranean regions throughout India, China, and Europe — essentially through all parts of
the then known world. During this lengthy period, numerous routes of opium administration had
been created; the two most widely used were dissolving the opium in solution such as wine (see
The Odyssey reference above by Homer) or other alcohol (e.g. laudanum) or vaporization of the
opium and inhalation of the opium vapors.

Figure 15. Dried opium. [Public Domain image
from the DEA, 2017]
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It wasn’t until the early 1800’s (CE) that advancements in the medicinal use of opium
occurred. In 1806 Friedrich Wilhelm Sertürner established the initial pharmacochemical
properties of a crystalline substance isolated from opium that he named Morphium, after the
Greek god of Dreams (this compound was later referred to as Morphine). The sleep inducing
and analgesic activity was established first in canine test animals and subsequently verified by
experimenter self-administration (Atanasov et al., 2015; Brownstein, 1993). This compound
represents the first isolated alkaloid and established the field of alkaloid-chemistry and, more
specifically, the field of morphine-chemistry. The structure of morphine remained elusive until
1952 when sufficient technological advancements finally allowed for the verification via total
synthesis by Marshall D. Gates (Gates, 1952) of the structure (Figure 16) proposed in 1925 by
Sir Robert Robinson (Gulland and Robinson, 1925) [For an excellent review summarizing the
historical developments of the total-synthesis of morphine since 1952 see: Rinner and Hudlicky,
2012.]. This was the culmination of a 146-year endeavor that resulted in a two column
publication that concluded: “With this, the first synthesis of morphine is complete.”

Figure 16. Structure of morphine.
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However, the utility of morphine in relieving pain was not without undesirable sideeffects, perhaps most notable has been that of addiction. The addictive use of opium has been
reported since antiquity in some of the earliest documents relating to the opium trade throughout
Asia, India, and Asia Minor (Brownstein, 1993). Even prior to the first total synthesis of
morphine in 1952, efforts had been directed at semi-synthetic structural modification to limit or
avoid addiction potential. The first reported
success was in 1874 with the synthesis of an
acetylated form of morphine (Wright, 1874).
However, it wasn’t until 1893 that Felix
Hofmann re-synthesized this same analogue
for the Bayer Company, who decided upon
a heroic name for the compound: Heroin
(from the German heroisch). Bayer
marketed Heroin (Figure 17) as lacking the
narcotism (i.e. addictive properties) seen
with morphine use — unfortunately this
ultimately was found to be inaccurate
(Hofmann, 2017).

Figure 17. Bayer Heroin bottle. [Public
Domain image from Mpv_51, 2017]
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Salvinorin A — A Novel Opioid
Pharmacological advancements within the field of morphine chemistry has yielded
thousands of analogues; however the ability to clearly separate desirable drug-like properties
such as antinociceptive activity from undesirable side-effects continues to remain elusive
(Kieffer, 2016). In this pursuit, overwhelmingly, MOR has been the primary opioid receptor
targeted for scientific study due to the effective antinociceptive activity of classical opioid
agonists that primarily mediate through this receptor subtype. However, there are numerous
adverse side-effects, beyond undesirable respiratory effects, MOR activation is complexed with
the dopaminergic reward pathway promoting euphoria, ultimately resulting in both physiological
and psychological dependence (Albert-Vartanian et al., 2016; Shook et al. 1990). Nevertheless,
MOR agonists continue to be the primary pharmacologic antinociceptive class of drugs clinically
used to treat pain. This has led to MOR agonists based on morphine-chemistry becoming the
most misused class of pharmaceutical agents in the world, which has stimulated interest in
targeting alternative opioid subtypes that are devoid of these physiologically adverse effects
(Negri et al., 2013).
The kappa opioid receptor (KOR) subtype, which is the target of salvinorin A, is widely
expressed throughout both central nervous tissues (brain and spinal cord), as well as, the
peripheral tissues, such as the gastrointestinal tract. Within the brain KOR is highly expressed in
the amygdala, hippocampus, hypothalamus, and striatum — regions associated with behavioral
functions including cognitive processing, emotional function, pain and stress response (Urbano
et al., 2014; Maillet et al.,2015). Furthermore, activation of KOR is generally not associated
with the physiologically adverse effects observed in MOR activation (i.e. physical dependence or
respiratory failure). This has generated interest in KOR becoming a potential clinical target for
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pain management, as well as, for the treatment of psychiatric conditions including anxiety and
depression. However, historically, KOR has been pharmacologically avoided due to associated
undesirable side-effects including anhedonia, dysphoria, and perceptiotropic effects (e.g.
hallucinations) (Lalanne et al., 2014; Maillet et al., 2015). Advancing within this paradigm there
has been significant work to elucidate the mechanism of salvinorin A activity with relation to
KOR due to the novel aspect of it being the first known non-nitrogenous opioid receptor agonist
(Roth et al., 2002).
Early computational studies were restricted to X-ray crystallographic data limited in
scope to “in-active” crystal structures derived from antagonist bound receptors (Roth et al.,
2002). The most common crystal structure utilized for this computational work has been human
KOR complexed with JDTic (PDB ID: 4DJH) (Polepally et al., 2014; Wu et al., 2012). To
address this limitation, site-directed mutagenic studies were undertaken to establish potential key
residues to aid in defining the salvinorin A binding pocket (Kane et al., 2006; Van et al., 2013;
Yan et al., 2005). Separately, these studies corroborated the importance of residues Y320 and
Tyr-139 of TM3 and residues Tyr-119, Tyr-312, Tyr-313, and Tyr-320 of TM7 as essential for
the binding of salvinorin A in KOR — it has been proposed that this aromatic cluster may form a
key binding pocket (Kane et al., 2008; Kane et al., 2006; Yan et al., 2005). Additionally, nonaromatic residues Gln-115 of TM2 and Ile-316 of
TM3 were also shown to be significant in
salvinorin A binding. In particular, loss of Ile-316
resulted in abolishment of salvinorin A binding at
KOR (Kane et al., 2008; Van et al., 2013; Yan et
Figure 18. Structure of U-69,593.
al., 2005). These residues were contrast with the
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prototypical U-69,593 (Figure 18) KOR subtype selective agonist and the endogenous peptide
dynorphin A, both of which displayed different requirements at these residues (Kane et al., 2006;
Yan et al., 2005).
Together these studies were used to establish putative key binding regions of salvinorin A
within KOR which suggested that the tricyclic core may vertically span (Figure 19) the receptor
between TM2 and TM7 (Kane et al., 2006; Yan et al., 2005). Perhaps most interestingly, these
residues differ significantly from the classical opioid ligand binding pocket centrally located in
the receptor, spanning TM3 and TM6, characterized by conserved Asp-138 and Asp147 residue
interactions — potentially indicating an unique binding mode for salvinorin A within the opioid

Figure 19. Putative binding orientation of salvinorin A structure within KOR
(Kane et al., 2006).
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receptor (Kane et al., 2008; Manglik et al., 2012; Surratt et al., 1994; Yan et al., 2005; Yuan et
al., 2015).
Expanding beyond a structural understanding of salvinorin A significant work has been
undertaken to build upon the initial pharmacological results reported by Bryan L. Roth in 2002
that established salvinorin A as the first known non-nitrogenous opioid receptor agonist that was
subtype selective for KOR (Roth et al., 2002). Their study used a competitive radioligand
binding affinity assay that employed [3H]-bremazocine and assessed salvinorin A at KOR
reporting a Ki of 4 nM. This was then followed by a functional assay that utilized
[35S]Guanosine 5’-(γ-thio)-triphosphate ([35S]GTP[γS]) as a measurable radioligand to assess the
activation of the receptor through binding of guanosine triphosphate (GTP) for which they
reported an EC50 of 1 nM for salvinorin A. This activity was subsequently corroborated in a
2004 study that reported similar values for salvinorin A at KOR with a binding affinity Ki of 18
nM and functional assessment of [35S]GTP[γS] binding activity reported at an EC50 of 0.63 nM
(Chavkin et al., 2004).
Toxicological assessment of salvinorin A (0.4 - 6.4 mg/kg, IP — a dose range
significantly greater than used by humans) for acute physiological and chronic histological
effects in mice established that there were no significant alterations in at any endpoint
(physiological measures: pulse pressure, galvanic skin response, cardiac conduction, body
temperature; histological measures: spleen, liver, kidney, brain, bone marrow, and blood).
Researchers concluded that the data suggested that potential toxicity from salvinorin A may be
quite low (Mowry et al., 2003). Furthermore, this lack of acute toxicity has been substantiated in
a number of subsequent clinical trials (table 2). The lack of overt toxicity has been largely
consistent in the literature, with one exception. In 2016 cytotoxicity of salvinorin A was
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reported for the first time from an in vitro MTT-based cell viability assay utilizing N27, A549,
Caco-2, HepG2, COS-7, and HEK-293 cell lines that was both dose-dependent (0.1, 1, 10, and
50 μM) and time-dependent (12-60 hours) across all cell lines (Marinho et al., 2016).

Table 2. Clinical trials with salvinorin A.
Route of
Administration

Dose
range

Number of
participants

Physiological Effects

Reference

Vaporization
/inhalation

200-500
µg

6

No negative effects reported.

Siebert 1994

Vaporization/
inhalation

0.37521µg/kg

4

No significant change to heart rate
or blood pressure.

Johnson et
al., 2011

Sublingual

1-4 mg

8

No effects, poor bioavailability by Mendelson et
sublingual administration.
al., 2011

Vaporization/
inhalation

100-1,017
µg/kg

Vaporization/
inhalation

0-12 mg

Vaporization/
inhalation

0.37521µg/kg

30

No significant change to body
temperature or systolic blood
pressure.

Addy et al.,
2012

10

No significant change to blood
pressure, heart rate, or euphoria.

Ranganathan
et al., 2012

8

No significant change to blood
pressure or heart rate. No resting
or kinetic tremors were observed.

MacLean et
al., 2013

Due to the high affinity and efficacy of salvinorin A at KOR a discriminative study was
undertaken in rhesus monkeys (Macaca mulatta) (Butelman et al., 2004). This study revealed
that subcutaneous administration of salvinorin A (0.001-0.032 mg/kg, SC) produced drug
discriminative effects in rhesus monkeys similar to the high-efficacy KOR agonist U-69,593. It
also demonstrated that KOR antagonist 5’-guanidinonaltrindole (GNTI) failed to antagonize the
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salvinorin A effect — possibly indicating that salvinorin A may possess a unique binding pose
within KOR distinct from that of classical opioids. Further in vivo pharmacological assessment
of salvinorin A (2 mg/kg, IV) in a mouse climbing model of motor coordination reported a
significant, but short-lived (≤ 15 minutes, with peak effects within five minutes), incoordination
similar to the U-69,593 KOR agonist control (Fantegrossi et al., 2005). This study observed a
reduction in motor-incoordination when salvinorin A groups were pretreated with norbinaltrophamine (nor-BNI; KOR antagonist). More interestingly however, this reduction was
not observed in the U-69,593 control group — once more bolstering the proposal that the binding
properties of salvinorin A within KOR may be unique.
The assessed in vivo pharmacological activities that are modulated by salvinorin A
continues to increase, this includes: antiproliferative, antipruritic, anti-inflammatory, antiprotozoal, gastrointestinal hypermotility, and neuroprotective effects in brain ischemia-models
— amongst others (Aviello et al., 2011; Calzada et al.,2015; Lozama et al., 2011; Vasiljevik et
al., 2014; Wang et al., 2005; Xin et al.,2016). However, our focus will be towards modulatory
effects of salvinorin A in models of antinociception, conditioned place aversion, and depression.
Pharmacological characterization of salvinorin A has demonstrated KOR-mediated
antinociceptive activity in mice. The first published report was in 2006 utilizing both chemo nociceptive and thermo-nociceptive assays (McCurdy et al., 2006). This study used two thermonociceptive models: tail-flick and hotplate, both revealing dose- and time-dependent
antinociceptive effects. Specifically, that salvinorin A possesses a short duration of activity,
peaking at ten minutes with a rapid return to baseline. This pattern of activity was also observed
in their chemo-nociceptive assay. Subsequent studies corroborated this pattern of
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antinociceptive activity in mice, including the short duration of activity (Ansonoff et al., 2006;
John et al., 2006).
Based upon previously establish effects of KOR agonists (e.g. U-69,593) that promote
aversive effects in place preference models, decrease drug reward effects through altered
dopamine levels and effect decreased cocaine self-administration, corresponding
pharmacological characterization was undertaken with salvinorin A as an atypical opioid (Chiara
and Imperato, 1988; Devine et al., 1993; Donzanti et al., 1992; Heidbreder et al., 1993). A 2005
study by the Zhang group used high doses of salvinorin A (1-3 mg/kg, IP) and established that
this treatment lowered dorsal striatum dopamine levels, measured in vivo in mice (C57BL/6J
mice) via microdialysis over a three hour duration post-treatment, in the caudate nucleus and
putamen. Moreover, this salvinorin A mediated reduction of striatal dopamine was completely
blocked by pretreatment with KOR antagonist nor-BNI. They also reported that at this dose
range salvinorin A induced both conditioned place aversion and decreased locomotor activity in
the test mice. They concluded that that the inhibitory effect on striatal dopamine levels by
salvinorin A administration may contribute to the observed conditioned place aversion and
lowered locomotor rates (Zhang et al., 2005). This conditioned place aversion was subsequently
demonstrated in a rat model using male Sprague-Dawley rats in 2014, notably at a lower dose
range (0.3-1 mg/kg, IP) than the previously used mouse model (Sufka et al., 2014).
However, a 2007 conditioned place preference study by Daniela Braida in zebrafish
(Danio rerio) reported that at a significantly lower dose range of 0.2-0.5 μg/kg of salvinorin A
promoted place preference in the associated drug-compartment. The highest dose assessed (80
μg/kg) in this study produced aversive effects in zebrafish (Braida et al., 2007). In 2008 the
Braida group translated this conditioned place preference study to male Wistar rats and reported
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a rewarding effect by salvinorin A at 0.1-40 μg/kg (SC) doses and an aversive effect at 160
μg/kg (SC) (Braida et al., 2008). They also utilized a non-competitive self-administration
paradigm and observed rewarding effects at doses 0.1-0.5 μg/intracerebroventricular (ICV)
infusion, but aversive effects at 1μg/infusion. Additionally, they were able to antagonize the
reward effect of salvinorin A, as expected, by pretreatment with KOR antagonist nor-BNI, but
more interestingly with cannabinoid receptor type-1 (CB1) antagonist rimonabant. However,
subsequent work in 2010 by the Walentiny group utilizing radioligand binding affinity,
[35S]GTP[γS] functional assessment, and calcium channel signaling revealed that this apparent
cannabinoid mediated activity by salvinorin A was not by direct activation — which corresponds
to earlier studies which reported no direct affinity/activation of cannabinoid receptors by
salvinorin A (Chavkin et al. 2004; Roth et al., 2002; Walentiny et al., 2010).
In 2001 it was observed that the overlapping distribution of KOR expression with
dopamine transporters (DAT) in striatal axons was strategically located to potentially modulate
dopamine uptake (Svingos et al., 2001). This study presented the first ultrastructural data
showing KOR localization and potential involvement in presynaptic regulation of dopamine.
Further work supporting the involvement of KOR dopamine modulation in conditioned place
aversion utilized conditional knock-out mice (DAT Cre-KOR KO) and determined that KOR
expression on dopaminergic neurons was essential for KOR-mediated conditioned place aversion
behavior (Chefer et al., 2013). Based upon the previously observed effect of decreasing
dopamine-levels and promotion of conditioned place aversion by salvinorin A it was proposed
that the mechanism of this activity may be through DAT/KOR modulation (Kivell et al., 2014).
Utilizing transfected EM4 cells the Kivell group in 2014 observed that salvinorin A only
promoted DAT activation in DAT/KOR co-expressing cells via measured change of 4-(4-
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diethylaminostyryl)-N-methylpyridinium iodide (ASP+ ) substrate accumulation in the test cells,
this accumulation was not observed in cells that only expressed DAT. Additionally, this altered
DAT function in DOR/KOR co-expressing cells was reversible with nor-BNI treatment. They
measured that this effect was differential between amine transporters as they observed a
decreased rate of ASP+ substrate accumulation with the serotonin transporter (SERT) and no
alteration with the norepinephrine transporter (NET).
Employing a surface biotinylation assay they reported that salvinorin A up-regulated
DAT surface expression in DAT/KOR co-expressing EM4 cells and that this effect was linked to
the extracellular signal regulated kinase-1/2 (ERK1/2) pathway as inhibition with PD98059 (an
ERK1/2 inhibitor) blocked this up-regulated DAT surface expression. Immunoblotting revealed
that salvinorin A promoted increased phosphorylation of ERK1/2, but not P38 mitogen-activated
protein kinase (P38 MAPK) signaling in their DAT/KOR co-expressing EM4 cells. Inhibition of
ERK1/2 by PD98059 prevented salvinorin A modulation of DAT ASP+ accumulation, while
inhibition of P38 MAPK by SB203580 (a P38 MAPK inhibitor) failed to alter salvinorin A DAT
effects which may indicate an ERK1/2 dependent mechanism of action for the observed
dopamine modulation by salvinorin A (Kivell et al., 2014).
With the established trend of KOR agonist induced dysphoria and the dopamine
modulation effects of salvinorin A it was posited that this may represent an approach towards
altering addictive responses observed with drugs of abuse, such as cocaine (Chartoff et al.,
2008). An initial study observed that in male Sprague-Dawley rats acute treatment with
salvinorin A (2 mg/kg, IP) resulted in attenuation of locomotor stimulant effects from cocaine.
Salvinorin A (0.3 mg/kg, IP) attenuation of locomotor stimulant effects from cocaine in SpragueDawley rats was also observed by the Morani group in 2012, but they further reported that
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salvinorin A treatment produced fewer adverse effects (such as sedation, aversion, and
depression) as commonly seen with other KOR agonist (e.g. U-69,593) (Morani et al., 2012).
Following this vein, use of a male Sprague-Dawley rat self-administration model found that
salvinorin A treatments (0.3-1 mg/kg, IP) attenuated cocaine self-administration, and had no
effect on operant response for sucrose reinforcement (Morani et al., 2009). This work was
subsequently translated to rhesus monkeys in 2014, where not only did salvinorin A attenuate
cocaine self-administration, but MOR agonist remifentanil self-administration as well, in a dosedependent manner (Freeman et al., 2014).
Lastly, for our specific pharmacological interest in salvinorin A there is the potential
modulatory role in depression. Numerous studies have indicated involvement of the opioid
system, and KOR in particular, in a diverse array of critical behavioral states, including:
addiction, anxiety, and depression (Al-Hasani and Bruchas, 2011; Lalanne et al., 2014; Ling et
al., 2011). Furthermore, there is an accumulated body of evidence demonstrating that KOR
activation can produce depression-like effects both in model organisms and, more importantly, in
humans (Carlezon et al., 2006; Ebner, et al., 2010; Lalanne et al., 2014; Pfeiffer et al., 1986). In
2006 it was reported that in forced swim tests (FST) and intracranial self-stimulation (ICSS)
tests, both standard depression-like models, in male Sprague-Dawley rats that administration of
salvinorin A (0.5-2.0 mg/kg, IP) would promote depression-like effects (Carlezon et al., 2006).
This study also observed that salvinorin A decreased striatal dopamine levels, but not serotonin
levels, within the nucleus accumbens — which is thought to play a critical role in reward
response related to addiction, as well as, depression and anxiety (Bewernick et al., 2010; Lalanne
et al., 2014; Olsen 2011). These results were corroborated in 2010 by the Ebner group also
utilizing the ICSS model in male Sprague-Dawley rats and administering salvinorin A at two
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doses 0.25 mg/kg and 2.0 mg/kg (IP), however they found only the high dose of 2.0 mg/kg
promoted the depression-like effects (Ebner, et al., 2010). They also reported a corresponding
decrease in striatal dopamine levels within the nucleus accumbens.
However, a 2009 study observed that salvinorin A (01-160.0 μg/kg, SC) produced
anxiolytic-like effects in male Sprague-Dawley rats when assessed in using an elevated plus
maze, anti-depressant-like effects in male Sprague-Dawley rats in a FST, and anti-depressantlike effects in male Albino Swiss mice assessed utilizing a tail suspension test (TST) — effects
which were antagonized by nor-BNI treatment (Braida et al., 2009). Ultimately, these studies
(Table 3) illustrate the pharmacological complexity observed in the study of salvinorin A: not
simply in various models/model organisms, but also with the range of observed effects that dose
and route of administration potentiate. Together this research demonstrates that additional
pharmacological characterization of salvinorin A and elucidation of mechanisms of activity are
needed.
Table 3. Summary of preclinical in vivo studies with salvinorin A.
Route of
TimeReference
Administration Course

Model Organism

Test Model

Activity

Dose

C57BL/6J mice

CPP

Aversive

1.0-3.2
mg/kg

IP

Zhang et
30 min al., 2005

Male Swiss mice

Tail-flick
1.0-4.0
Antinociceptive
test
mg/kg

IP

20 min

Male Swiss mice

1.0
Hotplate Antinociceptive
mg/kg

IP

McCurdy
10 min et al.,
2006

Male Swiss mice

Acetic acid
abdominal
0.5-2.0
Antinociceptive
constriction
mg/kg
assay

IP

15 min
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McCurdy
et al.,
2006

McCurdy
et al.,
2006

Table 3. Summary of preclinical in vivo studies with salvinorin A. (continued)
Model Organism

Test Model

Activity

Dose

ICV

15 min

Ansonoff
et al.,
2006

IT

10 min

John et
al., 2006

Depressive-like 0.25-2.0
effect
mg/kg

IP

15 min

Carlezon
et al.,
2006

C57BL6/Jx129S6
Tail-flick test Antinociceptive 7.5 μg
mice

CD-1 mice

Route of
TimeReference
Administration Course

13.9Tail-flick test Antinociceptive 23.1
nmol

Male SpragueDawley rats

FST

Male SpragueDawley rats

ICSS

Attenuates

0.5-2.0
mg/kg

IP

1 hr

Carlezon
et al.,
2006

Zebrafish

CPP

Rewarding

0.2-0.5
μg/kg

Dissolved

15 min

Braida et
al., 2007

Zebrafish

CPP

Aversive

80
μg/kg

Dissolved

15 min

Braida et
al., 2007

Wistar rats

CPP

Rewarding

0.1-40.0
μg/kg

SC

30 min

Braida et
al., 2008

Wistar rats

CPP

Aversive

160.0
μg/kg

SC

30 min

Braida et
al., 2008

Male SpragueDawley rats

Cocaine
induced
locomotor
activity

Attenuates

2.0
mg/kg

IP

2 hr

Chartoff
et al.,
2008

Male SpragueDawley rats

Cocaine
induced
locomotor
activity

Attenuates

0.3
mg/kg

IP

1 hr

Morani et
al., 2009

Male SpragueDawley rats

Cocaine selfadministration

Attenuates

0.3-1.0
mg/kg

IP

2 hr

Morani et
al., 2009

Male SpragueDawley rats

FST

Anti0.1depressant-like 160.0
effect
μg/kg

SC

15 min

Braida et
al., 2009
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Table 3. Summary of preclinical in vivo studies with salvinorin A. (continued)
Model
Organism

Test Model

Activity

Dose

Route of
TimeReference
Administration Course

Male SpragueDawley rats

Elevated plus Anxiolytic-like 0.1-160.0
maze
effects
μg/kg

SC

20 min

Braida et
al., 2009

Male SpragueDawley rats

TST

Anti0.1-160.0
depressant-like
μg/kg
effect

SC

6 min

Braida et
al., 2009

Male SpragueDawley rats

ICSS

Attenuates

2 mg/kg

IP

3 hr

Ebner, et
al., 2010

Male SpragueDawley rats

CPP

Aversive

0.3-1.0
mg/kg

IP

15 min

Sufka et
al., 2014

Rhesus
monkeys

Cocaine selfadministration

Attenuates

0.1
mg/kg/inj

IV

*Ten Freeman
choice
et al.,
sessions 2014
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CHAPTER 3: Salvinorin Analogues
In developing this pharmacological understanding of salvinorin A necessary work has
been undertaken to explore the chemistry of this compound. The first report of successful total
synthesis of salvinorin A occurred in 2007 by David A. Evans, consisting of a 29 step reaction
with an overall yield of 0.8% (Scheerer et al., 2007). This was subsequently improved by
Hisahiro Hagiwara in 2008, whose group achieved a reduction to 20 steps with a total yield
improvement to 0.95% (Nozawa et al., 2008). In 2009 the Hagiwara group reported a secondgeneration synthesis scheme that further reduced the number of steps to 13 and increased the
total yield to 2.8% (Hagiwara et al., 2009). However, in terms of cost effectiveness, the current
synthetic routes are still not competitive with the crude, but effective, isolation of salvinorin A
from the host plant Salvia divinorum, which typically yield in excess of 3% (Munro and
Rizzacasa, 2003; Sufka et al., 2014).
In addition, there are a growing number of natural products that have been isolated from
Salvia divinorum; however special interest has continued to be focused on those possessing
neoclerodane diterpenoid structures. To date there have been an additional nine salvinorin
compounds isolated, designated salvinorin A-J (Figure 20). However, with the exception of
salvinorin B, most have yet to be pharmacologically characterized to any significant degree (for
further information see references in Table 4).
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Figure 20. Natural salvinorin analogues.

Table 4. Natural salvinorin analogues
Natural Product

Reference

Salvinorin A

Grundman et al., 2007; Hanson, 2010; Ortega et al., 1982;
Shirota et al., 2006; Valdes et al., 1984

Salvinorin B

Grundman et al., 2007; Shirota et al., 2006; Valdes et al.,
1984

Salvinorin C

Grundman et al., 2007; Shirota et al., 2006

Salvinorin D

Bigham et al., 2003; Munro and Rizzacasa, 2003; Shirota et
al., 2006

Salvinorin E

Munro and Rizzacasa, 2003; Shirota et al., 2006

Salvinorin F

Munro and Rizzacasa, 2003; Shirota et al., 2006

Salvinorin G

Shirota et al., 2006

Salvinorin H

Shirota et al., 2006

Salvinorin I

Shirota et al., 2006

Salvinorin J

Kutrzeba et al.,2009
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Beyond these naturally occurring analogues, in exploring the structure-activity
relationship of salvinorin A there have been more than 300 analogues synthesized (for an
excellent review up to 2011 see: Cunningham et al., 2011). The majority of these analogues
have only been utilized as molecular probes targeting KOR, strictly being assessed for KOR
binding affinity. However, increasingly there has been a wider application of salvinoin A-based
molecular probes being used to characterize DOR and MOR via binding affinities, as well as,
measures of functional activity — with an increasing number progressing to applications within
in vivo pharmacological models (Aviello et al., 2011; Calzada et al.,2015; Cunningham et al.,
2011; Prisinzano and Rothman, 2008; Salaga et al., 2014; Vasiljevik et al., 2014; Wang et al.,
2005; White et al., 2015; Xin et al.,2016; Yan et al., 2009). Nevertheless, the majority of
research has focused on establishing a structure-activity relationship of the salvinorin A structure
at KOR.
Such research has revealed that the C(2)-position of salvinorin A represents a critical
pharmacophore feature for interaction at KOR. This is best exemplified by the hydrolysis of

Figure 21. Key pharmacophore
features of salvinorin A. Keasling
and Zjawiony, 2016. Reprinted
with permission.
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salvinorin A at the C(2)-position into the KOR-inactive natural product salvinorin B (Chavkin et
al., 2004). The general pattern amongst the current molecular probes indicates that analogues
whose functional C(2)-position substitutions are able to mimic the carbonyl oxygen
characteristics of the lead, salvinorin A, exhibit the highest binding affinities toward KOR
(Cunningham et al., 2011). Exploration of other prominent pharmacophore features (Figure 21)
of the salvinorin A structure have generally shown that structural modifications to the C(1)position [ketone], C(4)-position [carbomethoxy], C(12)-position [furan], and the C(17)-position
[lactone] result in a reduced KOR binding affinity, with only minor alterations at these positions
being tolerated (Cunningham et al., 2011; Lozama et al., 2011; Riley et al., 2014).
However, in 2005 while exploring the C(2)-position of salvinorin A via structural
modification the Prisinzano group reported one analogue exhibiting a surprising pharmacological
effect (Harding et al., 2005). The addition of an aromatic substitution at the C(22)-position
(Figure 22), through the introduction of a benzoyl group at C(2), reduced the subsequent binding
affinity towards KOR 47-fold (Ki of 90 nM) and reduced the functional activity 33-fold (EC50 of
1320 nM), as assessed utilizing a [35S] GTP[γS] binding assay (Table 5). However, this isn’t
surprising as most salvinorin A analogues exhibit a decreased or abolished KOR binding affinity.
What was surprising was that this substitution induced a MOR binding affinity (Ki of 12 nM)
and functional activity (EC50 of 500 nM), with the authors reporting this to be the first salvinorin
A-based agonist exhibiting high binding affinity towards MOR (Harding et al., 2005).
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Figure 22. Structure of Herkinorin.

Due to this novel activity, additional characterization was pursued in 2007, by which time
the compound had been named Herkinorin (Groer et al., 2007). This study revealed that
Herkinorin promoted phosphorylation of MAP kinases ERK1/2 in a dose-dependent manner,
similar to salvinorin A (see Chapter 2), but mediated through MOR and was able to be
antagonized by treatment with naloxone. They also reported that this ERK1/2 activation was
independent from β-arrestin-2 signaling and that Herkinorin does not promote the MOR
recruitment of β-arrestin-2 (Figure 23). This is of interest as there is a growing body of research
indicating β-arrestin-2 involvement in MOR regulation and that β-arrestin-2-KO mice exhibit
reduced opioid tolerance development, improved opioid-induced antinociception, and abolished
both respiratory suppression and morphine-induced constipation (Bohn et al., 1999; Bohn et al.,
2002; Przewlocka, et al., 2002; Raehal et al., 2005). Furthermore, this study showed that
Herkinorin did not promote MOR internalization (Figure 24). This is of interest as GPCR41

internalization has been associated with opioid-induced addiction and posited as a means of
receptor regulation (Bohn et al., 2004; Connor et al., 2004; Gainetdinov et al. 2004).

Figure 23. Herkinorin effect on β-arrestin-2 recruitment. Shows MOR mediated
translocation of β-arrestin-2-GFP by agonist treatments: DAMGO (1 μM) and
Herkinorin (2 μM). Groer et al., 2007. Reprinted with permission.

Figure 24. MOR agonist-mediated internalization. Shows effect of agonist
treatment on MOR-YFP in HEK-293 cells. Groer et al., 2007. Reprinted with
permission.

Subsequent pharmacological characterization of Herkinorin (1-10 mg/kg, SC) in male
Sprague-Dawley rats utilizing a formalin chemo-nociceptive model revealed dose-dependent
antinociception in both phase one (neurogenic pain caused by direct stimulation of the
nociceptors) and phase two (inflammatory pain caused by release of inflammatory mediators),
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with these antinociceptive effects being antagonized by naloxone pretreatment (Lamb et al.,
2012). Interestingly, they showed that contralateral administration failed to promote similar
antinociceptive effects — possibly indicating a peripheral restriction of Herkinorin to the site of
administration. They also utilized a tolerance development model to assess the effects of chronic
administration of Herkinorin (10 mg/kg, SC) as measured using the previous formalin assay and
found that it was still effective in both phases, potentially indicating a decreased tolerance
liability for this pharmacophore (see Table 5 for in vivo summary of Herkinorin).
Following this vein, an additional series of salvinorin A-based molecular probes were
generated where C(22)-position aromatic substitutions were explored (Tidgewell et al., 2008).
Of particular interest were the bicyclic addition of naphthalene-1 (Figure 25-1), naphthalene-2
(Figure 25-2) and the heteroaromatic addition of thiophene-2 (Figure 25-3) and thiophene-3
(Figure 25-4). While the steric bulk of the naphthalene addition was tolerated, the subtle esterlinkage shift from the substituent 1-postion to the substituent 2-position resulted in a preferential
binding affinity towards KOR or MOR, respectively (Table 5), with significantly reduced
binding affinity at other opioid subtypes. In the heteroaromatic thiophene analogues the

Figure 25. C(22)-position naphthalene and thiophene analogues of salvinorin A.
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KOR/MOR binding affinity is far more balanced, without clear preferential affinity towards a
single opioid receptor subtype. However, the preliminary activity is comparable to Herkinorin
(Table 5).
Together this data potentially indicates that the steric bulk of bicyclic C(22)-substitutions
on salvinorin A would not only be tolerated, but also that a subtle 1-/2-substituent-linkage
alteration may provide an approach for developing opioid receptor subtype-preferential
molecular probes. Additionally, the C(22)-heteroaromatic substitutions appears to be well
tolerated and from the preliminary in vitro data (Table 5) may yield analogues with increased
functional activity at KOR, as compared to the Herkinorin lead.
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Table 5. In vitro data summary of aromatic analogues of salvinorin A.
Analogue

Herkinorin

22

KOR

MOR

KOR

MOR

1170

90

12

1,320

500

±60

±2

±1

±150

±140

>10,000

—

—

Tidgewell
et al.,
2008

5,490

180

±640

±20

—

—

Tidgewell
et al.,
2008

1,380

260

10

±130

±20

±2

—

1,150

690

80

10

840

690

±30

±3

±1

±210

±60

580

70

10

1,120

1,680

±30

±2

±1

±170

±250

700

9

52

±101

±2

±9

—

—

>10,000

naphthalene-2 25-2

>10,000

25-3

thiophene-3

25-4

benzofuran-2
(P-3l)

26

PR-38

27

[35S]GTP[γS] binding, Reference
EC50 ± SD, nM

DOR

naphthalene-1 25-1

thiophene-2

Functional Activity

Binding affinity
Ki ± SD, nM

Figure

410
±40

— Indicates not assessed.
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±250

Tidgewell
et al.,
2008

Tidgewell
et al.,
2008
Tidgewell
et al.,
2008
Tidgewell
et al.,
2008
Polepally
et al.,
2014

These results supported further exploration as to the effect that incorporation of a fusedheteroaromatic substituent would have at the salvinorin A C(22)-position. This led to the
generation of a single analogue incorporating benzofuran-2 at this position (P-3l; Figure 26)
(Tidgewell et al., 2008). Compared to the previous aromatic substitutions, including that of the
Herkinorin lead, in vitro pharmacological assessment of P-3l revealed an increased binding
affinity by this fused-heteroaromatic analogue at all three opioid receptor subtypes (Table 5).
Additionally, when assessed utilizing a [35S] GTP[γS] binding assay, the P-3l analogue exhibited
a functional activity at KOR that was comparable to the Herkinorin lead and at MOR that was
comparable to the thiophene-2 analogue (Table 5).

Figure 26. Structure of 2-O-salvinorin B benzofuran-2carboxylate (P-3l).
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Separately, in 2014 while exploring the effect that incorporation of Michael acceptor-type
linkers at the C(2)-position of salvinorin A has on resulting aromatic analogues, the Zjawiony
group reported the generation of a cinnamoyl analogue designated as PR-38 (Figure 27)
(Polepally et al.,2014). This salvinorin A analogue displayed a preferential binding affinity for
KOR (Ki of 9 nM) and, interestingly, retained MOR binding affinity (Ki of 52 nM) (Table 5).
The high binding dual-affinity at KOR/MOR observed with the PR-38 compound encouraged
further in vivo pharmacological assessment.

Figure 27. Structure of 2-O-cinnamoylsalvinorin B (PR-38).

Utilizing a male BALB/c mouse model of irritable bowel syndrome (IBS) PR-38 (10-20
mg/kg, IP) was found to inhibit gastrointestinal hypermotility (Table 6) and colonic bead
expulsion (Salaga et al., 2014). Additionally, PR-38 (10 mg/kg, IP) was found to produce
antinociceptive effects in a male BALB/c mouse chemo-nociceptive model (acetic acid-induced
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abdominal writhing assay). Of particular interest is that this study utilized, in addition to
intraperitoneal administration, oral administration — a route of administration rarely examined,
due to the in-activity of the salvinroin A lead, and found PR-38 to be orally active. A subsequent
study employing a Swiss-Webster mouse pruritus model reported that PR-38 (10-20 mg/kg)
promoted antipruritic activity when administered both subcutaneously and orally (Salaga et al.,
2015).
Computational modeling was undertaken to examine the potential ligand-receptor
interactions that distinguish PR-38 from the salvinorin A lead (Polepally et al.,2014). Utilizing
the then available ‘inactive’ (i.e. antagonist co-crystallized) crystal structure of KOR complexed
with JDTic (PDB: 4DJH) the orthosteric binding site for the salvinorin tricyclic core was defined
utilizing residues: Asp-138, Gln-115, Thr-111, Val-108, Val-118, Val-134, and Val-135 —
these residues were supported by prior mutagenesis studies (Vardy et al., 2013; Wu et al., 2012).
This oriented the salvinorin tricyclic core towards TM2, with the C(2)-position interacting with a
binding pocket delineated with Asp-138, Met-142, and Tyr-139. What this model showed was
that the olefinic chain of the Michael acceptor-type linker is able to effectively fill a Asp-138,
Met-142, and Tyr-139 delineated pocket and allow the aromatic substituent to extend beyond
into a hydrophobic pocket bounded by TM3 and TM6, displaying key interactions with Met-142
and Ile-294. The researchers concluded that their model indicated that the C(2)-olefin portion of
PR-38 serves as hydrophobic linker and likely facilitates the engagement of the aromatic
substituent with a critical hydrophobic region within the receptor.
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Table 6. In vivo activity summary of aromatic analogues of salvinorin A.
Analogue

Model
Organism

Test Model

Activity

Dose

Route of
TimeReference
Administration Course

Male
Formalin assay
Sprague— phase 1
1-10
Herkinorin
Antinociceptive
Dawley
(neurogenic
mg/kg
rats
pain)

SC

1 hour

Lamb et
al., 2012

Male
Formalin assay
Sprague— phase 2
10
Herkinorin
Antinociceptive
Dawley (inflammatory
mg/kg
rats
pain)

SC

1 hour

Lamb et
al., 2012

Male
SpragueHerkinorin
Dawley
rats

SC

5 day

Lamb et
al., 2012

Tolerance
development

No tolerance 10
development mg/kg

PR-38

Male
Gastrointestinal
BALB/c
hypermotility
mice

Reduced
motility

10-20
IP and P.O.
mg/kg

20 Salaga et
min al., 2014

PR-38

Male
BALB/c
mice

Colonic bead
expulsion test

Inhibited
colonic
expulsion

10-20
mg/kg

IP

45 Salaga et
min al., 2014

PR-38

Male
BALB/c
mice

Acetic acidinduced
10
Antinociceptive
abdominal
mg/kg
writhing assay

IP

PR-38

SwissWebster
mice

Pruritus model

Antipruritic

10-20
mg/kg

SC

120 Salaga et
min al., 2015

PR-38

SwissWebster
mice

Pruritus model

Antipruritic

10
mg/kg

P.O.

120 Salaga et
min al., 2015

49

5 min

Salaga et
al., 2014

CHAPTER 4: Rationale, Specific Aims, and Expected Outcomes
The field of salvinorin chemistry represents novel and emerging field of opioid research.
The novelty of this field is derived from the lead pharmacophore: salvinorin A — a
pharmacologically unique compound which represents the first known non-nitrogenous KOR
subtype-selective opioid receptor agonist, exhibits a comparatively safe physiological profile
with no reports of toxicological effects in clinical trials, and, most importantly, has a steadily
growing body of literature indicating potentially useful clinical applications (e.g. antinociceptive,
anti-addictive, antipruritic, neuroprotective, etc.) (Aviello et al., 2011; Mowry et al., 2003; Roth
et al.¸ 2002; Wang et al., 2005; Xin et al.,2016). The emerging status of this field of research
entails both the relatively recent beginnings, arguably founded in 2002 with the identification of
the KOR target for salvinorin A by the Roth group, and subsequently with the growing body of
salvinorin analogues, exemplified by the recent development of aromatic analogues
(Cunningham et al., 2011; Groer et al., 2007; Harding et al., 2005; Polepally et al.,2014; Roth et
al.¸ 2002).
The development of salvinorin A aromatic analogues is of particular interest due to the
resulting range of pharmacological activity that has been reported. The 2005 report
incorporating a benzoyl substituent at the C(2)-position resulted in the first report of a nonnitrogenous high-binding affinity agonist at MOR — a compound subsequently named
Herkinorin (Groer et al., 2007; Harding et al., 2005). Ensuing pharmacological characterization
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of this aromatic salvinorin A analogue revealed that it did not promote β-arrestin-2 recruitment,
receptor internalization, or tolerance development — all undesirable activities commonly seen
with classical opioids (Groer et al., 2007; Lamb et al., 2012).
Subsequent incorporation of a cinnamoyl moiety at the C(2)-position of salvinorin A, a
compound designated as PR-38, resulted in a molecular probe with high-binding affinity towards
KOR/MOR (Table 5). More interestingly, however, PR-38 was uniquely found to be orally
active and promote both antinociceptive and antipruritic activities (Table 6) (Polepally et
al.,2014; Salaga et al., 2014; Salaga et al., 2015). Along these lines, incorporation of
naphthalene and thiophene substituents at the C(22)-position of salvinorin A, which conserve the
conjugation observed with the Michael acceptor-type linker found in PR-38, resulted in fusedaromatic and heteroaromatic analogues that display high-binding affinity, with subtype
selectivity observed in the case of the naphthalene analogues (Table 5). Lastly, represented by a
single molecular probe, the incorporation of a benzofuran-2 moiety (P-3l) at the salvinorin A
C(22)-position represents a potentially interesting line of research that has yet to be expanded.
Preliminary in vitro assessment of P-3l (Table 5) reveals that this analogue possesses
high-binding affinity, preferential for MOR/KOR, and functional activity as well (as assessed via
[35S] GTP[γS] binding). Structurally, it also retains key features of the preceding aromatic
analogues: it is a fused-heteroaromatic substituent that merges the fused-bicyclic feature of the
naphthalene analogues, the heteroaromaticity of the thiophene analogues, and the aromaticconjugated system observed with PR-38. This structural template affords a unique opportunity
to explore the effect of bioisosteric replacement [e.g. C/N/O/S] at the substituent 1-position and
the effect that substituent 2-/3-linkage with salvinorin A has on the ensuing pharmacology to
better characterize the opioid system. Due to the importance of this system, this series of
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molecular probes will help address the continuing need for new research tools capable of
ascertaining potential three-dimensional ligand binding requirements, functional activities, and
pharmacological consequences.
Specific Aims:
AIM 1. Synthesis of C(22)-fused-heteroaromatic salvinorin A analogues.
AIM 2. In vitro evaluation of analogues at the opioid receptors.
2a. Evaluation of ligand binding affinity at δ (Delta), κ (Kappa), and μ (Mu) opioid
receptors utilizing a competitive radioligand binding assay.
2b. Evaluation of ligand induced functional activity at opioid receptors measured by
[35S]GTP[γS] binding assay.
AIM 3. In vivo antinociceptive evaluation of analogues in mouse models
3a. Acetic Acid-induced Abdominal Writhing Assay
3b. Formalin Assay
3b. Opioid Antagonism Assay
3c. Hot Plate Assay

Expected Outcomes:


Design of a fused-heteroaromatic series of dual-affinity KOR/MOR salvinorin A-based
molecular probes.



Elucidation of structural motifs by which KOR/MOR affinity may preferentially be induced.



Determination of the pharmacological relevance of designated analogues towards mouse
models of antinociceptive activity.
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CHAPTER 5: Experimental Methods
Chemistry

Scheme 1. General synthesis procedure. Reagents and conditions: (A) Na2CO3, anhyd.
MeOH, stirred, r.t. 8 hr.; (B) appropriate carboxylic acid, DCC, DMAP, anhyd. CH2Cl2,
Ar atmo., stirred, r.t. 12 hr.
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General Synthesis Procedure
All reagents were purchased from commercial suppliers and, except where indicated,
were used without additional purification.
The general procedure used to deacetylate salvinorin A to salvinorin B was as follows: a
mixture of salvinorin A (3.5 g, 8.0 mmol, 1 equivalents) and sodium carbonate (3.4 g, 32.2
mmol, 4 equivalents) in absolute methanol (150 mL) was equipped with a stir bar and stirred at
room temperature overnight. The methanol was removed under reduced pressure and the residue
solubilized in dichloromethane (DCM, 500 mL). This solution was successively washed with
2N hydrochloric acid (HCl, 100 mL), sodium chloride solution (NaCl, 100 mL), and dried with
sodium sulfate (Na2SO4). The DCM was removed under vacuum and the resulting solid
resuspended in methanol, filtered and dried to yield salvinorin B (Tidgewell et al. 2004).
The general procedure used to generate this series of analogues outlined (Scheme 1) was as
follows: a solution of salvinorin B (0.10 g, 0.26 mmol, 1 equivalents), appropriate carboxylic
acid (0.51 mmol, 2-3 equivalents), 1,4-dicyclohexylcarbodimide (DCC; 0.132 g, 0.61 mmol, 2
equivalents), and catalytic amount of 4-(dimethylamino)pyridine (DMAP) were added to a round
bottom flask equipped with stir bar and then flushed with Argon, before being sealed under
Argon atmosphere. To the reaction vessel was added anhydrous DCM (5 mL) this was placed in
an ice bath (0°C) and while stirring allowed to reach room temperature overnight. After
checking with TLC (short/long UV and vanillin stain; Sorbent Technologies, Atlanta, GA; Silica
G TLC Plates w/UV254, 200 μm thickness, polyester backed) to ensure completion of reaction,
material was partitioned between deionized water and the organic DCM layer dried under
reduced pressure to yield the crude reaction material ready for chromatographic purification
(Polepally et al. 2014; Tidgewell et al. 2008).
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Chromatography
The general procedure used to purify analogues in this series was as follows: the crude
reaction material was first processed via vacuum liquid chromatography (VLC) across silica gel
(Sorbent Technologies, Atlanta, GA; Silica Gel, 200g, Porosity: 60 Å, Particle Size: 230 x 400
mesh) using a 10% solvent gradient from 100% n-hexane to 100% ethyl acetate. The collected
fractions were checked with TLC (UV and vanillin stain) and combined based on characteristic
staining profile. Combined fractions were then dried under vacuum via rotary evaporator and
loaded on onto a Sephadex LH-20 gravity column (GE Healthcare Life Sciences, Chicago, IL;
100 g) equilibrated in chloroform:methanol (1:1). The collected fractions were checked with
TLC (UV and vanillin stain) and combined based on profile. Combined fractions were then
dried under vacuum via rotary evaporator and loaded on onto a C18 reverse phase silica gel
column (Acros Organics, NJ; C18 Silica Gel, 200g, 23%C, ca. 1.2 mmol/g, particle size: 40-63
μm) that was equilibrated water:methanol (90:10). This column was processed using a 5% VLC
solvent gradient to 100% methanol, with the column stripped with methanol:ethyl acetate (95:5)
to yield the target analogue. This general chromatography procedure was validated via a Waters
2487 Analytical HPLC utilizing Phenomenex Hydro-RP C18 column (Phenomenex; Torrance,
CA;10x250mm, Synergi Hydro-RP 10um, 80 Å) and a YMC-Polyamine II column (YMC
America, Inc.; Allentown, PA;150x10mm) using an elution rate of 3 ml/minute. We processed
the analogue utilizing an isocratic acetonitrile:water (70:30) solvent system first across the C18
column (Figure 28) and then the polyamine column (Figure 29). This general chromatography
procedure was found to result in material of ≥95% purity by UV detection and a percent yield
typically between 30-38% for the resulting analogues.
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Phenomenex Hydro-RP C18 column

Figure 28. Representative C18-HPLC-UV chromatogram.

YMC-Polyamine II column

Figure 29. Representative NH2 -HPLC-UV chromatogram.

Structural Elucidation
Nuclear Magnetic Resonance (NMR) spectra were obtained for both carbon (13C) and proton
(1H) of all compounds measured using a Bruker Avance NMR spectrometer (400 UltraShield, 54
mm standard magnet bore; Billerica, MA) equipped with a 3mm probe with spectra recorded at
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101 MHz and 400 MHz, respectively (Appendices A-C). All samples were analyzed using
deuterated chloroform as the solvent. High-resolution mass spectrometric (HRMS) data was
obtained employing a Bruker MicroTOF-ESI Mass Spectrometer (Billerica, MA) via direct
injection with samples (1 mg/ml) solubilized in methanol.

Pharmacological Characterization
In Vitro Methods
Opioid Receptor Binding Affinity
Preliminary and secondary binding affinities were determined utilizing established
competitive radioligand binding assays. Briefly, we utilized stably transfected HEK-293 cells
expressing human opioid receptor subtypes DOR, KOR, and MOR. Stably transfected cell lines
were maintained on Dulbecco’s Modified Eagle Medium (DMEM) nutrient media supplemented
with fetal bovine serum (10%), hygromycin B (300 mg/mL), L-glutamine (2mM), and penicillinstryptomycin (0.5%) under a 5% atmosphere of carbon dioxide maintained at a temperature of
37°C. Membranes were prepared by scraping cells in a Tris-HCl buffer, followed by sonication
facilitated homogenization and centrifugation (Leon et al.,2013; Polepally et al., 2014).
In the preliminary binding assay the new analogues were assessed at 10 µM test
concentrations with competitive incubation with [3H]-Enkephalin, [3H]-U‑69,593, or [3H]DAMGO for DOR, KOR, or MOR, respectively. For controls, unlabeled DPDPE, norBinaltorphimine, and DAMGO were used, once more for DOR, KOR, and MOR, respectively.
After termination of the incubation cycle and multi-well washing, microplate scintillation values
were determined using a TopCount NXT analyzer (Leon et al.,2013). This first assay was used
to calculate percent inhibition of the analogue to see if it met the 70% threshold to proceed to
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secondary binding affinity evaluation. Analogues meeting the 70% threshold were subsequently
evaluated in the secondary bind affinity assay that utilized a 12-step serial dilution from 100 μM
to 0.5 nM to calculate the equilibrium dissociation constant (Ki). Analogues possessing a Ki
≤300 nM were evaluated for functional activity utilizing a [35S]GTP[γS] binding assay.

Opioid Receptor Functional Activity
Methods similar to those in competitive radioligand binding assays functional assays
were used for the [35S]GTP[γS] binding assay. Utilizing [35S]GTP[γS] as a measurable
radioligand of GTP we measured the exchange of GDP at the inactive G-protein-coupled
receptor (DOR, KOR, or MOR) for [35S]GTP[γS] as a measure of receptor activation (i.e.
functional activity) by ligands possessing a Ki ≤300 nM binding affinity in the secondary
competitive radioligand binding assays. As before, controls consisted of nor-Binaltorphimine
and DAMGO for KOR and MOR, respectively and were assessed via serial dilution to calculate
a dose response curve to determine analogue effect (i.e. full agonist, partial agonist, etc.) and to
determine effective concentrations (EC50). All in vitro assays were performed in triplicate (Leon
et al.,2013).

In Vivo Methods
Test animals
Test animals used in the following in vivo assays were male Swiss Webster mice (adults,
21-24g), obtained from Harlan Laboratories. Mice received water and food ad lib, while housed
in groups of five. Housing facilities were maintained on a lighting schedule of 12 hours (0600 to
1800).
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I. Antinociceptive Related Assays
Acetic Acid-induced Abdominal Writhing Test
Groups of mice (n = 10) were treated by gavage (P.O.) with vehicle (10% DMSO, 10
ml/kg, vehicle control), test analogue (1, 3, 10 mg/kg, P.O.), indomethacin 20 mg/kg or
morphine 10 mg/kg (positive control for antinociceptive activity), 60 minutes before the
administration of acetic acid solution (0.6% v/v; 10 ml/kg, IP) (Koster et al., 1959). The number
of writhing movements produced in each group in the 30 minute test period was counted and the
results were expressed as mean ± SEM as percentage of control group. A significant reduction in
the number of writhing movements was considered to be a positive antinociceptive response.
Formalin Assay
The experimental groups of mice (n = 7) were treated by gavage (P.O.) with vehicle
(10% DMSO, 10 mL/kg, vehicle control), test analogue (1, 3, 10 mg/kg, P.O.), indomethacin 20
mg/kg (positive control for antinociceptive activity in the second phase), 60 minutes before, or
subcutaneously (SC) with morphine 10 mg/kg (positive control for antinociceptive activity in the
first and second phases), 30 minutes before the administration of formalin (20 μl, 3% v/v) in the
right hind paw (Melo et al., 2005). After the formalin phlogistic agent injection, the mice were
placed into an acrylic test box with a mirror located under the box to enable observation of the
formalin-injected paw for 30 minutes. Assessment of pain reaction time (i.e. time until paw
licking behavior) was observed for two periods: 0 to 5 minutes — the first phase (neurogenic
pain caused by direct stimulation of the nociceptors) and from 15 to 30 minutes — the second
phase (inflammatory pain caused by release of inflammatory mediators) (Hunskaar et al., 1985).
Results were expressed as mean ± SEM, in seconds.
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Opioid Antagonism Assay
To examine the involvement of opioids receptors in the observed antinociceptive activity
in the formalin-induced pain assay. The experimental group of mice (n = 7) were pretreated with
saline (0.9 %, 10 ml/kg, IP, negative control) or naloxone 3 mg/kg, IP, opioid antagonist). After
15 minutes the mice were treated with vehicle (20 % DMSO, 10 ml/kg, P.O., vehicle control),
test compound (10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive control/opioid agonist).
Sixty-minutes after oral administration, or 30 minutes after subcutaneous administration, the
mice were administrated formalin (20 μl, 3 % v/v) in the right hind paw. The pain reaction time
(time until paw licking behavior) was observed in the first phase (neurogenic pain) of formalin
assay (Hunskaar et al., 1985).

Hot Plate Assay
The hot plate test was performed as previously described by Woolfe and MacDonald
(1944). The latency (in seconds) to reaction to the thermal stimulus, expressed by lifting of the
hind paws accompanied by licking or flinch was measured using hot plate (Insight®, Ribeirão
Preto, São Paulo, Brazil) set at 55.5 ± 0.5 °C. The mice were divided into four experimental
groups (n = 8): vehicle (10% DMSO, 10 ml/kg, P.O.), test analogue (1, 3, 10 mg/kg, P.O.) or
morphine (5 mg/kg, P.O., positive control for antinociceptive activity). The latency baseline was
measured 30 minutes before of the treatments (time -30) and immediately after of the treatments
(time 0) for each animal. After treatment, the latency to pain reaction was measured at 30, 60, 90,
120, 150 and 180 minutes. A cut-off of 20 seconds was used to prevent the possibility of harm to
the test animals. Results were expressed as means ± SEM, in seconds, at the assessed times.
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II. Antidepressant Related Assays
Forced Swim Test
Test mice (n = 10) were evaluated by a forced swin test (FST) after oral administration
of vehicle (10% DMSO, 10 mL/kg, P.O.), test analogue (1, 3, 10 mg/kg, P.O.) or imipramine (15
mg/kg, P.O.) (Fajemiroye et al., 2014; Porsolt et al., 1977). Treated mice were placed
individually in a cylindrical container of 18 cm diameter filled with water to the height of 30 cm
in height, total volume of 7.6 L, at 24 ± 2°C. Video from six-minute test sessions was recorded
with the swimming and immobility time measured for statistical analysis.
Tail Suspension Test
A modified version of tail suspension test (TST) was employed with test mice (n = 10)
administered oral treatment of either vehicle (10% DMSO, 10 mL/kg, P.O.), test analouge (1, 3,
10 mg/kg, P.O.), or imipramine (15 mg/kg, P.O.) (Steru et al., 1985). Treated mice were
suspended using adhesive tape placed two centimers from the tip of the tail one hour after
administartions of selected treatment. Video from six-minute test sessions was recorded and the
immobility time scored and analysed.

III. Anxiolytic Related Assay
Open Field Test
A circular open field arena with base area 62 cm2 and eight equal sectorial-divisions enclosed
with a 50 cm high wall was used to evaluate exploratory activity of the mice (Fajemiroye et al.,
2015; Fajemiroye et al., 2014). Test mice (n = 10) were treated via oral administration either
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vehicle (10% DMSO, 10 mL/kg, P.O.), test analogue (1, 3 or 10 mg/kg, P.O.), diazepam (5
mg/kg, P.O.) one hour prior to the test session (five-minute duration) in the open field.
Diazepam was used as a positive control in this model as this dose reliably induced anxiolyticlike effects. Video from five-minute test sessions was recorded and the exploratory activities
scored and analysed.

Computational Modeling
Model Design
We utilized the active-state agonist-bound μ-opioid receptor (MOR) X-ray crystal
structure (PDB ID: 5C1M) published in late 2015 to develop an in silico homology model of the
κ-opioid receptor (KOR) in its active state (Huang et al., 2015; Vardy et al., 2013). The full
sequence of human KOR was downloaded from the Uniprot website
(http://www.uniprot.org/uniprot/P41145) and used to define key residue difference between
KOR and MOR. We utilized chain A of the 5C1M crystal structure, in which MOR is bound to
the morphinan agonist BU72 as a template for generating multiple homology models. Alignment
of the KOR and MOR sequences using ClustalW revealed that KOR and 5C1M possessed a 67%
sequence identity and 81% sequence similarity after alignment (Figure 30). Additionally, a
critical disulfide bridge located in the extracellular-loop 2 of KOR between Cys-131 and Cys210 (Cys-140 and Cys-217 in MOR) was included in the model generation (Polepally et al.,
2014). We generated ten preliminary models using the knowledge-based method implemented
in 2016 Schrödinger suite. Loop regions of these ten models were refined using the Prime
module implemented in the Schrödinger suite and the quality of the protein structure models
were assessed by Ramachandran plotting. This analysis revealed that only one model expressed
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all amino acids in the favored/allowed regions as defined in the Ramachandran plot (Figure 31)
— therefore this was the model utilized for subsequent optimization (Schrödinger, 2017).
The crystal structure of active state MOR obtained from the Protein Data Bank (PDB ID:
5C1M) was further optimized for docking by adding hydrogen atoms, removing waters,
including structure truncation of side chains for Lys-269, Glu-270, and Arg-273, generating the
physiologically appropriate protonation state and hydrogen-bond assignments. Receptor
optimization utilized hydrogen-only restrained minimization was performed using the OPLS3
force field (Schrödinger, 2016). Additionally, we defined the putative active-site by
incorporating key amino residues previously identified through corroborating point-mutation
studies [Gln-115, Tyr-119, Tyr-139, Tyr-312, Tyr-313, Ile-316 and Tyr-320] (Kane et al., 2006;
Van et al., 2013; Yan et al., 2005).
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Figure 30. Sequence alignment of KOR with the MOR template. Identical residues
are in red, while similar residues are in blue. Helical regions are labeled and
indicated using yellow background.
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Figure 31. Ramachandran plot of the best KOR protein model
showing the dihedral angles of the amino acids.

Opioid Receptor Docking Studies
Structures of the salvinorin analogues were sketched in Maestro and energy-minimized
using the LigPrep module implemented in the Schrödinger software package using the OPLS3
force field (Schrödinger, 2016). A docking receptor grid for the KOR homology model was
generated using the centroid of the key residues identified through previous point-mutation
studies lining the putative binding site: Gln-115, Tyr-119, Tyr-139, Tyr-312, Tyr-313, Ile-316
and Tyr-320 (Kane et al., 2008; Kane et al, 2006; Yan et al, 2005). Extra-precision docking
without constraints was performed utilizing the Glide module of the Schrödinger software
(Schrödinger, 2016).
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ADME/T Calculations
Considering physiochemical properties such as absorption, distribution, metabolism,
excretion, and toxicity (ADME/T) at the early stage of the drug development process is
important to avoid downstream drug development issues. Advances in the computational field
have steadily improved predictive methods for calculating ADME/T properties (Tao et al., 2015;
Wang et al. 2015). As such, pharmaceutically important ADME/T properties of the analogue
series were selected (Table 7) for calculated evaluation using the Schrödinger QikProp module
implemented in the Maestro software, using LigPrep OPLS3 force field energy-minimized
structures for each analogue (Schrödinger, 2016).

Statistical Analyses
The data was analyzed by a two-way analysis of variance (ANOVA) followed by
Dunnett’s post hoc test or Bonferroni’s post hoc test. In vitro data is expressed as Ki or EC50 ±
SEM and in vivo data is expressed as mean ± SEM, with differences being considered
statistically significant when P-values were less than 0.05. Statistical analysis was performed
with GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA, USA).
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Table 7. Schrödinger QikProp Module ADME/T Descriptors
Properties

Description

Recommended
Range

Molecular weight
(Da)

Molecular weight of the molecule

130.0 – 725.0

PSA (Å2)
Number of
rotatable bonds
QPlogPoct
(octanol/water)
QPlogS
(aqueous
solubility)

Van der Waals surface area of polar
nitrogen and oxygen atoms
Number of non-trivial (not CX3), nonhindered (not alkene, amide, small ring)
rotatable bonds
Predicted octanol/water partition
coefficient
Predicted aqueous solubility, log S in
mol/dm

Predicted Caco-2 cell permeability in
nm/sec
[representative for GI-blood barrier]
Predicted MDCK cell permeability in
QPPMDCK
nm/sec
(nm/s)Γ
[representative for blood-brain barrier]
Lipinski Rule-of- Number of violations of Lipinski’s rule of
five
5 violations
Predicted IC50 value for blockage of
QPlogHERG
HERG K+ channels
Prediction of binding to human serum
QPlogKhsa
albu
Predicted human oral absorption on 0 to
% Human Oral
100% scale
Absorption
Predicted central nervous system activity
CNS
on a –2 (inactive) to +2 (active) scale.
Data adapted from: Schrödinger, 2016.
QPPCaco (nm/s)
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7.0 – 200.0
0.0 – 15.0
-2.0 – 6.5
-6.5 – 0.5
<25 is poor
>500 is great
<25 is poor
>500 is great
Max. 4
Above -5.0
-1.5 – 1.5
>80 is high
<25 is poor
-2.0 – +2.0

CHAPTER 6: Results and Discussion
Chemistry

Figure 32. Structure of 2-O-salvinorin B benzofuran-2carboxylate (P-3l).

Utilizing the general synthesis procedure (outlined in Chapter 5: Experimental Methods)
with the appropriate benzofuran-2-carboxylic acid compound 2-O-salvinorin B benzofuran-2carboxylate (P-3l; Figure 32) was synthesized and yielded an amorphous white solid; 1H NMR
(400 MHz, Chloroform-d) δ 7.73 – 7.56 (m, 4H), 7.56 – 7.26 (m, 7H), 6.38 (d, J = 1.9 Hz, 1H),
5.48 (ddd, J = 32.9, 11.5, 6.7 Hz, 3H), 3.82 – 3.66 (m, 5H), 2.99 – 2.76 (m, 2H), 2.62 – 2.42 (m,
5H), 2.30 (s, 2H), 2.23 – 2.02 (m, 4H), 1.83 (dd, J = 11.1, 4.3 Hz, 2H), 1.74 – 1.55 (m, 5H), 1.46
(s, 5H), 1.21 (d, J = 32.8 Hz, 5H).

13

C NMR (101 MHz, CDCl3) δ 201.34, 171.47, 171.13,

158.41, 156.00, 144.41, 143.70, 139.44, 128.04, 126.83, 125.23, 123.96, 123.00, 115.14, 112.43,
108.41, 75.77, 72.05, 64.02, 53.55, 52.01, 51.33, 43.26, 42.22, 38.19, 35.49, 30.85, 18.17, 16.50,
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15.20. HRMS (m/z): [M+Cl] calculated: 569.159, observed: 569.233. Molecular formula:
C30H30O9. Molecular weight: 534.19.

Figure 33. Structure of 2-O-salvinorin B 1Hindole-2-carboxylate (AK-1401).

Compound 2-O-salvinorin B 1H-indole-2-carboxylate (AK-1401; Figure 33) was
synthesized utilizing the general synthesis procedure with indole-2-carboxylic acid and yielded
an amorphous white solid; 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 1H), 7.71 (d, J = 8.1
Hz, 1H), 7.51 – 7.31 (m, 5H), 7.17 (t, J = 7.6 Hz, 1H), 6.40 (s, 1H), 5.54 (dd, J = 11.8, 4.9 Hz,
1H), 5.42 (t, J = 10.0 Hz, 1H), 3.76 (s, 3H), 2.89 – 2.79 (m, 1H), 2.53 (dt, J = 28.9, 8.6 Hz, 3H),
2.28 – 2.15 (m, 2H), 2.11 (d, J = 10.6 Hz, 1H), 1.86 (d, J = 11.6 Hz, 1H), 1.68 – 1.57 (m, 3H),
1.48 (s, 2H), 1.20 (s, 2H).

13

C NMR (101 MHz, CDCl3) δ 201.73, 171.51, 171.08, 160.57,

143.72, 139.43, 137.12, 127.43, 125.97, 125.90, 125.23, 122.79, 121.03, 111.88, 110.23, 108.39,
75.36, 72.05, 64.20, 53.64, 52.04, 51.43, 43.46, 42.22, 38.22, 35.52, 30.99, 18.17, 16.51, 15.22.
HRMS (m/z): [M-H] calculated: 532.572, observed: 532.174. Molecular formula: C30H31NO8.
Molecular weight: 533.58.
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Figure 34. Structure of 2-O-salvinorin B
benzo[b]thiophene-2-carboxylate (AK-1402).
Compound 2-O-salvinorin B benzo[b]thiophene-2-carboxylate (AK-1402; Figure 34) was
synthesized utilizing the general synthesis procedure with benzo[b]thiophene -2-carboxylic acid
and yielded an amorphous white solid; 1H NMR (400 MHz, Chloroform-d) δ 8.16 (s, 1H), 7.93 –
7.85 (m, 2H), 7.53 – 7.38 (m, 4H), 6.40 (dd, J = 1.8, 0.9 Hz, 1H), 5.53 (dd, J = 11.7, 5.2 Hz, 1H),
5.40 (dd, J = 11.1, 8.8 Hz, 1H), 3.76 (s, 3H), 2.91 – 2.78 (m, 1H), 2.61 – 2.45 (m, 4H), 2.30 –
2.07 (m, 4H), 1.89 – 1.78 (m, 2H), 1.76 – 1.56 (m, 5H), 1.41 – 1.24 (m, 2H), 1.19 (s, 4H).

13

C

NMR (101 MHz, CDCl3) δ 201.44, 171.52, 171.12, 161.72, 143.72, 142.53, 139.47, 138.63,
131.53, 127.27, 125.72, 125.21, 125.05, 122.78, 108.42, 75.87, 72.05, 64.12, 53.61, 52.03, 51.41,
43.39, 42.21, 38.22, 35.51, 30.90, 28.15, 18.17, 16.51, 15.22. HRMS (m/z): [M+Cl] calculated:
585.589, observed: 585.205. Molecular formula: C30H30O8S. Molecular weight: 550.62.
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Figure 35. Structure of 2-O-salvinorin B benzofuran3-carboxylate (AK-1403).

Compound 2-O-salvinorin B benzofuran-3-carboxylate (AK-1403; Figure 35) was
synthesized utilizing the general synthesis procedure with benzofuran-3-carboxylic acid and
yielded an amorphous white solid; 1H NMR (400 MHz, Chloroform-d) δ 8.34 (s, 1H), 8.09 –
7.99 (m, 1H), 7.58 – 7.49 (m, 1H), 7.44 – 7.27 (m, 4H), 6.41 – 6.36 (m, 1H), 5.55 – 5.37 (m,
2H), 3.73 (s, 3H), 2.89 – 2.77 (m, 1H), 2.57 – 2.39 (m, 3H), 2.28 (s, 1H), 2.21 – 2.04 (m, 3H),
1.84 – 1.73 (m, 1H), 1.72 – 1.53 (m, 4H), 1.21 (d, J = 36.4 Hz, 5H).

13

C NMR (101 MHz,

CDCl3) δ 201.86, 171.61, 171.18, 162.09, 155.61, 151.75, 143.68, 139.51, 125.51, 125.25,
124.36, 122.02, 113.63, 111.76, 108.47, 75.08, 72.02, 63.95, 53.50, 51.99, 51.29, 43.28, 42.16,
38.14, 35.46, 30.98, 29.67, 18.16, 16.49, 15.20. HRMS (m/z): [M+Cl] calculated: 569.5294,
observed: 569.7652. Molecular formula: C30H30O9. Molecular weight: 534.56.
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Figure 36. Structure of 2-O-salvinorin B
benzo[b]thiophene-3-carboxylate (AK-1405).

Compound 2-O-salvinorin B benzo[b]thiophene-3-carboxylate (AK-1405; Figure 36) was
synthesized utilizing the general synthesis procedure with benzo[b]thiophene -2-carboxylic acid
and yielded an amorphous white solid; 1H NMR (400 MHz, Chloroform-d) δ 8.58 – 8.48 (m,
2H), 7.92 – 7.85 (m, 1H), 7.59 – 7.37 (m, 5H), 6.40 (dd, J = 1.9, 0.9 Hz, 1H), 5.57 – 5.40 (m,
3H), 3.75 (s, 4H), 2.85 (dd, J = 9.2, 7.6 Hz, 2H), 2.60 – 2.44 (m, 5H), 2.28 (s, 1H), 2.24 – 2.06
(m, 3H), 1.90 – 1.77 (m, 2H), 1.75 – 1.58 (m, 5H), 1.47 (s, 4H), 1.19 (s, 4H).

13

C NMR (101

MHz, CDCl3) δ 201.96, 171.62, 171.14, 161.37, 143.70, 140.02, 139.48, 137.87, 136.55, 125.98,
125.57, 125.25, 125.18, 124.63, 122.56, 108.45, 75.14, 72.05, 64.10, 53.63, 52.01, 51.39, 43.39,
42.21, 38.20, 35.50, 31.05, 18.18, 16.52, 15.23. HRMS (m/z): [M+Cl] calculated: 585.1394,
observed: 585.5306. Molecular formula: C30H30O8S. Molecular weight: 550.17.
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Figure 37. Structure of 2-O-salvinorin B 1Hindene-2-carboxylate (AK-1406).

Compound 2-O-salvinorin B 1H-indene-2-carboxylate (AK-1406; Figure 37) was
synthesized utilizing the general synthesis procedure with 1H-indene-2-carboxylic acid and
yielded an amorphous white solid;; 1H NMR (400 MHz, Chloroform-d) δ 7.89 – 7.83 (m, 1H),
7.58 – 7.49 (m, 2H), 7.45 – 7.31 (m, 4H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.53 (dd, J = 11.6, 5.1
Hz, 1H), 5.33 (t, J = 10.0 Hz, 1H), 3.75 (d, J = 5.2 Hz, 5H), 2.87 – 2.77 (m, 1H), 2.56 (dd, J =
13.5, 5.2 Hz, 1H), 2.49 – 2.39 (m, 2H), 2.28 – 2.06 (m, 3H), 1.88 – 1.79 (m, 1H), 1.76 – 1.55 (m,
4H), 1.48 (s, 3H), 1.18 (s, 3H).

13

C NMR (101 MHz, CDCl3) δ 202.13, 171.62, 171.14, 163.67,

144.96, 143.71, 142.79, 142.49, 139.45, 135.73, 127.94, 126.98, 125.23, 124.30, 123.63, 108.41,
74.98, 72.06, 64.13, 53.67, 51.99, 51.44, 43.43, 42.19, 38.30, 38.23, 35.50, 31.01, 18.18, 16.48,
15.23. HRMS (m/z): [M+Cl] calculated: 567.1794, observed: 567.4084. Molecular formula:
C31H32O8. Molecular weight: 532.21.
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Pharmacological Results

In Vitro Results
Briefly, the generated C(22)-fused-heteroaromatic salvinorin A analogues were
pharmacologically characterized utilizing the following in vitro scheme: analysis in a primary
competitive radioligand binding affinity assay at DOR/KOR/MOR, analogues that met the 70%threshold inhibition proceeded to the secondary competitive radioligand binding affinity assay to
establish Ki values, with analogues exhibiting Ki ≤300 nM proceeding to the [35S]GTP[γS]
binding assay as a measure of functional activity to established EC50 at the respective receptor.
In summarizing the in vitro data (Table 8), it was observed that benzo[b]thiophene-2 and
benzo[b]thiophene-3, AK-1402 and AK-1405, respectively, failed to meet the 70%-threshold
inhibition in the primary competitive radioligand binding affinity assay at any of the opioid
receptors. This is of interest as they represent the fused-heteroaromatic analogues to the
previous high-binding affinity heteroaromatic thiphene-2 and thiophene-3 analogues (Table 3).
The next comparable analogue is P-3l, the benzofuran-2 analogue which in our assays
displayed increased binding affinity at DOR and KOR (5-fold and 10-fold, respectively), as well
as, increased functional activity at both KOR and MOR (14-fold and 8-fold, respectively) —
when compared to previous reported values (Table 5). However, this variation may be
accounted for by the use of different cell-lines used to express the respective sourced human
opioid receptor cDNA, as those used by the Tidgewell group report DOR activity for their
salvinorin A control which was not observed in ours (Leon et al.,2013; Tidgewell et al., 2008).
Shifting the ester-type link from the substituent 2-position to the substituent 3-position in
AK-1403, our benzofuran-3 analogue, resulted in abolished DOR/KOR binding affinity and
strict MOR binding affinity (Ki of 149 nM). However, the functional activity was reduced when

74

compared to P-3l (MOR EC50 of 210 nM reduced to 950 nM) — however, the assessed
functional activities of both benzofuran-analogues, P-3l and AK-1403, were higher than that
previously reported by Tidgewell for P-3l (MOR EC50 of 1,680 nM)(Tidgewell et al., 2008).
Incorporation of the indene-2 substituent, AK-1406, resulted in binding affinity at all
assessed receptors (Table 8), however only DOR and MOR met the secondary binding affinity
threshold of Ki ≤300 nM — with a clear preference for MOR (DOR Ki of 279 and MOR Ki of 8).
Assessment of functional activity by [35S]GTP[γS] binding further corroborated this MOR
preference with a MOR EC50 of 85 nM and a DOR EC50 of 894 nM.
Of interest was the indole-2 substituent, AK-1401, as this analogue incorporates a
nitrogen into salvinorin A — a pharmacophore noted as being unique for being nonnitrogenous. This promoted a MOR/KOR dual-binding affinity, with a 100-fold preference for
MOR and functional assessment revealed a MOR EC50 of 187 nM.
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Table 8. In vitro data summary of C(22)-fused-heteroaromatic salvinorin A analogues.
Functional Activity

Compound

[35S]GTP[γS] binding,
EC50 ± SEM, nM

Binding Affinity
Delta Delta Kappa Kappa Mu
pKi
Ki
pKi
Ki
pKi
±SEM (nM) ± ±SEM (nM) ±SEM
SEM
±SEM

DPDPE

7.742 18.12
0.0707 1.71

U-69,593

—

—

DAMGO

—

—

Salvinorin
A

—

—

P-3l

—

Mu
Ki
(nM)
±SEM

DOR

KOR

MOR

—

—

2.526
0.427

—

—

—

—

—

25.62
4.12

—

—

—

7.204
1.21

—

—

—

—

21.36
2.85

367.0
66.9

80.88
8.03

210.7
36.5

7.979
0.1262

10.49
1.79

—

—

187.5
51.7

—

8.964 1.087
0.0905 0.132
—

—

8.748
1.787
0.0995 0.0239

9.021 0.9534
0.1034 0.133

—

7.007 98.36 8.140 7.242 7.670
0.2051 28.1 0.0663 0.642 0.0993
5.998 1005
0.1246 169

AK-1401

—

—

AK-1402

—

—

—

—

—

—

—

—

—

AK-1403

—

—

—

—

6.826
0.070

149.40
14.0

—

—

950.7
458.4

AK-1405

—

—

—

—

—

—

—

—

—

8.068
0.063

8.553
0.715

894.6
50.4

—

85.0
7.15

AK-1406

6.553 279.9 6.266 541.9
0.137 51.9 0.086 62.8

—

— indicates that 70% inhibition in primary binding affinity
assay was not achieved
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indicates that Ki
≤300 nM in
secondary binding
affinity was not
achieved

In Vivo Results
I.

Antinociceptive Related Assays
Based on the preceding in vitro results analogues three of the substituent 2-position

analogues were selected for in vivo characterization focused towards potential antinociceptive
effects: P-3l, AK-1401, and AK-1402.

Acetic Acid-induced Abdominal Writhing Assay
As outlined in the experimental section (Chapter 5) the the first chemo-nociceptive mode
we employed was an acetic acid-induced abdominal writhing assay. The mice (n = 10) were
treated with vehicle (10ml/kg, P.O.) as a negative control, indomethacin (20 mg/kg, P.O.) or
morphine (10 mg/kg, P.O.) as positive controls. The three selected fused-heteroaromatic
salvinorin A analogues were administered at three test doses: 1, 3, 10 mg/kg (P.O.). These
treatments were 60 minutes prior to the administration of acetic acid solution (IP) and subsequent
30 minute test period in which writhing movements were measured. All three of the assessed
analogues produced statistically significant reduction in writhing movements with P-3l (Figures
38) active at 3 and 10 mg/kg, and AK-1401(Figures 39) and AK-1402 (Figures 40) producing
statistically significant reductions at all three tested doses. These writhing reductions are
interpreted as a measure of antinociciptive effects in this model.
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Figure 38. Acetic acid-induced abdominal writhing assay results: P-3l.
Effect of P-3l (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes
in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.) were
used as positive control. Vertical bars represent mean ± SEM of cumulated
writhing (%) in 30 min for each experimental group. * P ≤ 0.05 using ANOVA
followed by Dunnet test.

Figure 39. Acetic acid-induced abdominal writhing assay results: AK-1401.
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced
writhes in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.)
were used as positive control. Vertical bars represent mean ± SEM of cumulated
writhing (%) in 30 min for each experimental group. * P ≤ 0.05 using ANOVA
followed by Dunnet test.
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Figure 40. Acetic acid-induced abdominal writhing assay results: AK-1402.
Effect of AK-1402 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced
writhes in mice. Indomethacin (20 mg/kg, P.O.) and morphine (10 mg/kg, P.O.)
were used as positive control. Vertical bars represent mean ± SEM of
cumulated writhing (%) in 30 min for each experimental group. *P ≤ 0.05 using
ANOVA followed by Dunnet test.

Formalin Assay
The second chemo-nociceptive model we employed was a formalin assay which allows us to
examine both direct neurogenic pain and subsequent inflammatory pain. As outlined in the
experimental section (Chapter 5) the mice (n = 7) were administered vehicle (10ml/kg, P.O.) as a
negative control in both phases, morphine (10 mg/kg, SC) as a positive control in first and
second phases, or indomethacin (20 mg/kg, P.O.) as a positive control in the second phase. The
three selected fused-heteroaromatic salvinorin A analogues were administered at three test doses:
1, 3, 10 mg/kg (P.O.). All treatments, except for morphine were administered 60 minutes prior
to test, with morphine being administered 30 minutes prior. Once administered the formalin
phlogistic agent mice were observed for two periods: 0 to 5 minutes — the first phase (direct
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neurogenic pain) and from 15 to 30 minutes — the second phase (inflammatory pain). Both P-3l
(Figure 41) and AK-1401 (Figure 42) produced statistically significant reduction in paw licking
behavior at all three doses, in both neurogenic and inflammatory (1st and 2nd) phases.
Interestingly, in this model, AK-1402 (Figure 43), failed to promote a reduction of paw licking
behavior during the secondary (inflammatory) phase and was only active in the neurogenic phase
at the higher doses of 3 and 10 mg/kg.

Figure 41. Formalin assay results: P-31.
Effect of P-3l (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10
µmoL/kg P.O.) on the licking time of formalin test, in mice, during the first (0-5 min)
and second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction
time, in seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05
(compared with 2nd phase control group) using ANOVA followed by Dunnet test.
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Figure 42. Formalin assay results: AK-1401.
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine
(10 µmoL/kg P.O.) on the licking time of formalin test, in mice, during the first (0-5
min) and second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction
time, in seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05
(compared with 2nd phase control group) using ANOVA followed by Dunnet test.
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Figure 43. Formalin assay results: AK-1402.
Effect of AK-1402 (1, 3, 10 mg/kg P.O.), indomethacin (20 mg/kg P.O.) and morphine (10
µmoL/kg P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in
seconds. * P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with
2nd phase control group) using ANOVA followed by Dunnet test.
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Opioid Antagonism Assay
To evaluate the preceding formalin assay first phase results for opioid pathway
involvement we utilized naloxone antagonist model (as outline in the Experimental Methods,
Chapter 5). Briefly, we pretreated mice (n =7 ) with either saline (10 ml/kg, IP) as a negative
control or naloxone (3 mg/kg; IP) as the opioid antagonist. After 15 minutes the mice received
one of four treatments: vehicle, or one of the three selected fused-heteroaromatic salvinorin A
analogues (10 mg/kg; P.O.) from the previous assay (P-3l, AK-1401, or AK-1402). Pretreatment
with naloxone was found to antagonize the reduction previously observed in licking behavior in
the first phase of the formalin assay in a statistically significant manner with all three analogues
(Figures 44, 45, 45), supporting the involvement of the opioid receptors in mediating the
antinociciptive effect in this model.

Figure 44. Opioid antagonism assay results: P-3l.
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the P31 10 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤
0.05 (compared control group) and # P ≤ 0.05 (compared with respectively treated
group) using ANOVA followed by Dunnet test.
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Figure 45. Opioid antagonism assay results: 1401.
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK1401 10 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05
(compared control group) and # P ≤ 0.05 (compared with respectively treated group)
using ANOVA followed by Dunnet test.
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Figure 46. Opioid antagonism assay results: 1402.
Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK1402 3 mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in
mice. Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05
(compared control group) and # P ≤ 0.05 (compared with respectively treated group)
using ANOVA followed by Dunnet test.
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Hot Plate Assay

As our thermo-nociceptive model we utilized a hot plate assay. In this model, mice (n =
8) were treated either with vehicle control (10 ml/kg, P.O.), morphine (5 mg/kg, P.O.) as a
positive control, or one of the three selected fused-heteroaromatic salvinorin A analogues (P-3l,
AK-1401, AK-1402) assessed at 1, 3, and 10 mg/kg (P.O.). A 30 minute pretreatment latency
baseline was established for each test mouse. After treatment latency response to thermal pain
was measured every 30 minutes (0-180 minutes). In this model, both P-3l (Figure 47) and AK1401 (Figure 48) produced statistically significant increase in latency response to thermal pain at
doses 3 and 10 mg/kg for the entire 180 minute test duration. AK-1402 also produced a

Figure 47. Hot plate assay results: P-3l.
Effect of P-31 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O.- positive control)
on the hot plate test, in mice (n = 8). The values were expressed as mean ± SEM of
the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group,
according to two-way ANOVA followed by Bonferroni’s post-hoc test.
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statistically significant increase in latency response to thermal pain at 3 and 10 mg/kg for 150
minutes of the test period before returning to baseline by 180 minutes (Figure 49). Additionally,
both P-3l and AK-1402 also showed activity at the 1 mg/kg dose from 60 to 150 minutes.

Figure 48. Hot plate assay results: AK-1401.
Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive
control) on the hot plate test, in mice (n = 8). The values were expressed as mean ±
SEM of the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to
control group, according to two-way ANOVA followed by Bonferroni’s post-hoc
test.
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Figure 49. Hot plate assay results: AK-1402.
Effect of AK-1402 (1, 3, 10 mg/kg P.O.) or morphine (10 mg/kg, P.O., positive
control) on the hot plate test, in mice (n = 8). The values were expressed as mean
± SEM of the latency to nociceptive behavior, in seconds. *P ≤ 0.05 compared to
control group, according to two-way ANOVA followed by Bonferroni’s post-hoc
test.
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II.

Antidepressant Related Assays
Based upon the initial in vitro results establishing the preference of AK-1401 for MOR

(100-fold more than KOR) and the MOR functional activity at EC50 of 187 nM, as well as, the in
vitro antinociceptive activities established in both chemo-nociceptive and thermo-nociceptive
models this analogue was selected for further characterization for potential antidepressant-like
activity.

Forced SwimTest
Our first model used to assess potential antidepressant-like effects of AK-1401 was the
forced swim test that measures effect on swimming time and immobility. Test mice (n = 10)
were treated with either a vehicle control (10 ml/kg, P.O.), imipramine (IMI, 15 mg/kg, P.O.) or

Figure 50. Forced swim test, swimming time results: AK-1401.
The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility
time (C) in the forced swimming test. Each column represents the mean ± S.E.M. of 10
animals. *P < 0.05, *P < 0.01 or *P < 0.001 versus vehicle treated group (one way
ANOVA followed by Dunnett´s test).
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AK-1401 at 1, 3, or 10 mg/kg (P.O.) and assessed one hour after for activity. AK-1401 was
found to produce statistically significant increases in swimming time (Figure 50) and reduced
immobility time (Figure 51) at doses 3 and 10 mg/kg. These effects are interpreted as
antidepressant-like activity in this model.

Figure 51. Forced swim test, immobility time results: AK-1401.
The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility
time (C) in the forced swimming test. Each column represents the mean ± S.E.M. of 10
animals. *P < 0.05, *P < 0.01 or *P < 0.001 versus vehicle treated group (one way
ANOVA followed by Dunnett´s test).
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Tail Suspension Test
Our second model used to assess potential antidepressant-like effects of AK-1401 was a
modified version of tail suspension test (TST) that measures immobility. Test mice (n = 10)
were treated with either a vehicle control (10 ml/kg, P.O.), imipramine (IMI, 15 mg/kg, P.O.) or
AK-1401 at 1, 3, or 10 mg/kg (P.O.) and assessed one hour after for activity. Once more, AK1401 was found to produce statistically significant activity (i.e. reduction in immobility) at doses
3 and 10 mg/kg (Figure 52) — these results further indicate antidepressant-like activity.

Figure 52. Tail suspension test results: AK-1401.
The effect of oral administration of AK-1401 at the doses of 1, 3, 10 mg/kg and
positive control imipramine (IMI) 15 mg/kg or vehicle on immobility time in the
tail suspension test (one-way ANOVA followed by Dunnett’s test).
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III.

Anxiolytic Related Assay

Open Field Test
Lastly, we utilized a circular open field test (OFT) to assess the potential anxiolytic-like
effects of AK-1401 on exploratory activity with the endpoints being: freezing time, total
sectorial crossing, rearing number, and center crossing. Test mice (n = 10) were treated with
either vehicle (10 ml/kg, P.O.), diazepam (DZP, 5 mg/kg, P.O.), or AK-1401 at 1, 3, or 10 mg/kg
(P.O.). However, AK-1401 was largely ineffective at altering these behaviors (Figures 53 and
54), except for center crossing (Figure 54-D) where it significantly increased this exploratory
behavior. While these results largely indicate that AK-1401 does not promote anxiolytic-like
effects in mice, the effect on exploratory behavior may suggest that further anxiolyitc
characterization would be advisable.
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Figure 53. Open field test results, Freezing time and Total crossing: AK-1401.
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive control
diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay on freezing
time (A), the total crossing (B), number of rearing events. Each column represents the
mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001 versus vehicle treated group
(one way ANOVA followed by Dunnett´s test).
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Figure 54. Open field test results, Number of rearing and crossing at the center:
AK-1401.
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive
control diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay on
freezing time (C) and crossing at the center of the open-field (D). Each column
represents the mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001 versus
vehicle treated group (one way ANOVA followed by Dunnett´s test).
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Computational Modeling
Opioid Receptor Docking Studies
KOR Docking Studies
The Schrödinger Prime protein-structure prediction program was utilized to calculate
the molecular mechanics with generalized born surface area (MM-GBSA) of both salvinorin A
and AK-1401 complexed with KOR (Schrödinger, 2017; Vilar et al., 2010). As expected from
in vitro binding affinity studies (Table 8; in vitro established salvinorin A KOR Ki of 0.9 nM and
AK-1401 KOR Ki of 1,005 nM), our docking calculations indicated a lower binding free energy
for the KOR/salvinorin A complex (Binding Energy = −61.674 kcal/mol) than for the KOR/AK1401 complex (Binding Energy = −53.046 kcal/mol). Additionally, this optimized KOR model
showed that AK-1401 possessed a binding orientation analogous to salvinorin A except at the
C(22)-position indole moiety (Figure 55). This predicted orientation of the AK-1401 indole
moiety differed from the acetoxy moiety of salvinorin A due to increased solvent exposure, lack
of significant hydrophobic and polar interactions — which may account for the lower
experimentally derived KOR binding affinity of AK-1401compared to salvinorin A (Table 8).
The predicted binding pose indicated the fused-tricyclic core of salvinorin A is vertically
oriented towards TM2, TM3, and TM6 and surrounded, primarily, by the side chains of residues:
Gln-115, Ile-135, Asp-138, Tyr-139, Met-142, Val-230, Ile-294, and Ile-316 (Figure 56).
Salvinorin A exhibited strong hydrophobic interactions with Tyr-139, Met-142, Ile-294, and Ile316. The ketone moiety at the C(1)-position hydrogen-bonded with Gln-115. The C(12)position furan moiety interacted in a deeper sub-pocket characterized by key interactions with
Tyr-320 and Trp-287 through aromatic π-π stacking and exhibited hydrophobic interactions with
residues: Val-108, Met-142, Ile-290, and Ile-316. The C(2)-position acetoxy-group was shown
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Figure 55. Overlay of AK-1401 (cyan carbons) and salvinorin A (yellow carbons).

to hydrogen-bond with Gln-115 and was delineated by residues: Ile-135, Asp-138, and Cys-210.
The C(4)-position carbomethoxy was situated in a small pocket bound by residues: Lys-227,
Glu-297, Leu-212 and Tyr-312 (Figure 57). Interestingly, this optimized docking pose was
found to correspond well with a previously reported site-directed mutagenesis derived docking
pose of salvinorin A (Kane et al., 2006). The primary difference observed between these two
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proposed docking poses is that at the C(2)-position the Kane group reported a Tyr-313
hydrophobic interaction while in our model the interaction is calculated to be with Gln-115
(Figure 57).

Figure 56. Predicted binding oreintation of salvinorin A (yellow carbons)
into the active-state KOR model (key active site residues shown with grey
carbons).
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Figure 57. Predicted key-residue interactions of KOR/salvinroin A complex.
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MOR Docking Studies
Similar to the method described for our KOR model a receptor grid was prepared for
MOR centered on the centroid of the co-crystallized agonist (BU72) of PDB: 5C1M. The amino
acid terminus (residues Gly-52-Met-65) of the active state MOR forms a lid over the putative
orthosteric site. Therefore we utilized the Induced Fit docking protocol within the Schrödinger
software suite to examine the potential MOR/AK-1401orientation and interactions, chosen due to
the activity established in the previous in vitro and in vivo assays. This model was optimized
utilizing the OPLS3 force field optimization and extra-precision docking mode of the Glide
module in the Schrödinger software suite, without the inclusion of specified docking constraints
— to allow for a comprehensive docking range to be examined.
The docking results, and MM-GBSA calculations for each, provided a range of putative
binding poses for AK-1401 within the active state MOR model. The best pose based on
calculated Glide Gscore value (Glide Gscore = −9.887) and binding energy value (Binding
Energy = −96.604 kcal/mol) revealed that AK-1401 exhibited strong hydrogen-bonding
between Gln-124 and the amine on the C(22)-indole, as well as at the ketone moiety of the C(2)position (Figure 58). In this pose, the C(22)-indole moiety was bounded by key residues (Tyr128, Trp-318, Phe-320 and Ile-322) forming a hydrophobic-pocket. In addition, the C(22)-indole
moiety also participated in aromatic π-π stacking with His-319 and Trp-318. The C(12)-position
furanyl moiety showed hydrogen-bonding with Gly-52 and aromatic π-π stacking with Phe-221.
The C(4)-position carbomethoxy was oriented towards a sub-pocket delineated by residues:
Asp-147, Tyr-148 and Met-151. Interestingly, this pose of AK-1401 (Figure 59) did not show
direct interactions, such as hydrogen-bonding, with Asp-147 — an interaction which is largely
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conserved for MOR classical opioid ligands but not observed with salvinorin A (Manglik et al.,
2012; Yuan et al., 2015; Yuan et al., 2013).

Figure 58. Predicted key-residue interactions of MOR/AK-1401 complex.
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Figure 59. The putative binding mode of AK-1401 (yellow carbons) into the
active-state MOR model (key active site residues shown with grey carbons).
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ADME/T Calculations
Lastly, due to the high degree of homology with this bioisosteric C(22)-fusedheteroaromatic salvinorin A analogue series the Schrödinger QikProp module calculated
ADME/T properties were similarly homologous (Table 9) and, largely, indicated reasonable
drug-like properties for this series (with Schrödinger QikProp recommend range values derived
from a dataset comprised of 95% of currently marketed drugs; Schrödinger, 2016). The
predicted logP and logS values were in the recommended range to indicate this series would
likely possess good aqueous solubility and low lipophilicity. Additionally, except for a single
violation (due to high molecular weights) this series also follows Lipinski’s Rule of Five,
supporting ease of solubility and oral availability of these compounds. This was further
supported by high Percent Human Oral Absorption values (all above 80% which predicts good
oral availability) — maintained by our in vivo models by effective use of P.O. administration
route. The only calculated property of concern was the QPlogHERG values, which were outside
the recommend range — indicating potential hERG potassium channel interaction and possible
drug-induced cardiac effects (i.e. cardiac arrhythmia) (Sanguinetti and Tristani-Firouzi, 2006).
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Table 9. Schrödinger QikProp Module ADME/T Calculations.
Properties
Molecular
weight (Da)
PSA (Å2)†
Number of
rotatable
bonds
QPlogPoct
(octanol/wat
er)‡
QPlogS
(aqueous
solubility)§
QPPCaco
(nm/s)¶
QPPMDCK
(nm/s)Γ
Lipinski
Rule-of-5
violations
QPlogHER
GΔ
QPlogKhsa
% Human
Oral
Absorption
CNS

P-3l

AK1401

AK1402

AK1403

AK1404

AK1405

AK1406

AK1407

534.56

533.57

550.62

534.56

533.57

550.62

532.58

532.58

139.16

142.93

129.44

137.60

142.63

127.73

129.76

127.91

3

3

3

3

3

3

3

3

3.74

4.14

4.32

3.67

4.37

4.40

4.23

4.18

-5.54

–6.70

-6.19

-5.15

-6.24

-6.15

-6.06

-5.99

435.39

270.09

434.81

498.42

292.29

555.87

498.23

517.88

201.38

120.19

321.46

233.07

130.90

500.18

232.97

242.92

1

1

1

1

1

1

1

1

-6.49

–6.70

-6.41

-6.20

-6.30

-6.31

-6.42

-6.34

0.21

0.71

0.43

0.16

0.63

0.42

0.44

0.42

83.16

81.74

86.51

83.78

83.71

88.92

87.04

87.09

-2

-2

-2

-1

-2

-1

-2

-2

Physicochemical properties calculated using QikProp. Range is for 95% of known
drugs. Recommended range, based on that of 95% of marketed drugs: Molecular
weight (130–725 Da); † Van der Waals surface area of polar nitrogen and oxygen
atoms (7–200 Å2); ‡ Predicted octanol/water partition coefficient (−2–6.5); §
Predicted aqueous solubility, log S (−6.5–0.5); ¶ Predicted apparent Caco-2 cell
permeability (<25 nm/s poor; >500 nm/s great); Γ Predicted apparent MDCK cell
permeability (<25 nm/s poor; >500 nm/s great); Δ Predicted IC50 value for blockage
of HERG K+ channels (it is a serious concern if below −5);  Prediction of binding to
human serum albumin (−1.5–1.5 acceptable). CNS range: -2 (inactive) to +2
(active).
Schrödinger, 2017.
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CHAPTER 7: Conclusions
This study further supports the importance of the continued development of new
salvinorin A analogues as essential research tools to ascertain potential three-dimensional ligand
binding requirements, functional activities, and pharmacological consequences mediated through
the clinically important opioid receptors. This series of pharmacologically evaluated C(22)fused-heteroaromatic salvinorin A analogues (i.e. P-3l, AK-1401, AK-1402, AK-1403, AK1405, and AK-1406) revealed a range of activities. Though it would be difficult to conclude a
definitive structure-activity-relationship, trends are observed in the generated data that allow for
a number of tentative conclusions:

o

This study corroborates the effect that aromaticity has on inducing MOR binding affinity
in salvinorin A — a lead pharmacophore typified by KOR selectivity.
With one caveat: this trend was not observed with either of the
benzo[b]thiophene-analogues (AK-1402 and AK-1405) as neither produced minimum
inhibition in the primary competitive radioligand binding assay. However, subsequent in
vivo antinociceptive assessment of AK-1402, in both chemo-nociceptive (acetic acidinduced abdominal writhing assay and formalin assay, first-phase) and thermonociceptive (hot plate assay) models, revealed statistically significant activity mediated
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through the opioid receptors (determined via the opioid antagonism assay). — indicating
further assessment would be advisable

o This study further supports the potential for oral administration of aromatic analogues of
salvinorin A — a lead pharmacophore typified by oral inactivity.
This route of administration was previously employed for PR-38 in models of
gastrointestinal hypermotility and antipruritic activity (Table 6) and was the elected route
of effective administration (i.e. active) in our study for P-3l, AK-1401, and AK-1402 in
respective antinociceptive and antidepressant-like assays.

o This study further bolsters the development of salvinorin A analogues towards potential
clinical applications, specifically, antinociception and depression, with increased
durations of activity when compared to other salvinorin compounds.
This line of development has a steadily growing body of literature indicating
potentially useful clinical applications (e.g. antinociceptive, anti-addictive, antipruritic,
neuroprotective, etc.) of not only the lead, salvinorin A, but an increasing number of
analogues, such as Herkinorin (avoids β-arrestin-2 recruitment, receptor internalization,
and tolerance development), PR-38 (orally active, promotes both antinociceptive and
antipruritic activities) and, in this study, P-3l, AK-1401, and AK-1402 (respectively,
promoting statistically significant antinociceptive and antidepressant-like effects).
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o Lastly, the computationally derived ADME/T properties of this study indicated potential
hERG potassium channel interaction by this series of salvinorin A analogues as all
predicted values were outside of the recommended safety range.
While this pharmacological contradiction has not been reported in the salvinorin
class, due to the potential for drug-induced cardiac effects (i.e. cardiac arrhythmia)
mediated through hERG potassium channel interaction, assessment would be advisable
prior to further drug development considerations.
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Calculated 1H NMR of AK-1401

Calculated 1H NMR of AK-1402

124

Calculated 1H NMR of AK-1403

Calculated 1H NMR of AK-1404
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Calculated 1H NMR of AK-1405

Calculated 1H NMR of AK-1406
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Calculated 1H NMR of AK-1407
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Calculated 13C NMR of Salvinorin A
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Calculated 13C NMR of AK-1401
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Calculated 13C NMR of AK-1403
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Calculated 13C NMR of AK-1405

Calculated 13C NMR of AK-1406
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Calculated 13C NMR of AK-1407
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APPENDIX C:
Measured 1H and 13C NMR Spectra
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Measured 1H NMR of Salvinorin A
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Measured 13C NMR of Salvinorin A
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Measured 1H NMR of P-3l
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Measured 13C NMR of P-3l
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Measured 1H NMR of AK-1401

139

Measured 13C NMR of AK-1401
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Measured 1H NMR of AK-1402
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Measured 13C NMR of AK-1402
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Measured 1H NMR of AK-1403
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Measured 13C NMR of AK-1403
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Measured 1H NMR of AK-1405
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Measured 13C NMR of AK-1405
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Measured 1H NMR of AK-1406
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Measured 13C NMR of AK-1406
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APPENDIX D:
In Vitro Datasets

149

Binding Affinity of Salvinorin A
Kappa

Kappa

pKi +/- SEM

Ki (nM) +/- SEM

Salvinorin
A

9.0210.1034

0.95340.133

Naloxone
HCl

8.9640.0905

1.0870.132

Compound

150

S a lv in o rin A

% B in d in g

C o n tro l
100

50

0
-1 6

-1 4

-1 2

-1 0

-8

-6

lo g [ H L -0 1 0 ] M

IC50

Salvinorin A
1.907e-009

Control
4.221e-009

Ki

Salvinorin A
9.534e-010

Control
2.110e-009

150

-4

Binding Affinity of P-3l
Delta

Delta

pKi +/- SEM

Ki (nM) +/- SEM

P-3l

7.0070.2051

98.3628.1

Naloxone
HCl

7.7420.0707

18.121.71

Compound

% Binding

150

P-3I
Control

100

50

0
-14

-12

-10

-8

-6

-4

log [HL-010] M

IC50

P-3I
1.967e-007

Control
3.624e-008

Ki

P-3I
9.836e-008

Control
1.812e-008
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Binding Affinity of P-3l
Kappa

Kappa

pKi +/- SEM

Ki (nM) +/- SEM

P-3l

8.1400.0663

7.2420.642

Naloxone
HCl

8.9640.0905

1.0870.132

Compound

150

P -3 I

% B in d in g

C o n tro l
100

50

0
-1 4

-1 2

-1 0

-8

-6

lo g [ H L -0 1 0 ] M

IC50

P-3I
1.448e-008

Control
4.844e-009

Ki

P-3I
7.242e-009

Control
2.422e-009
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-4

Binding Affinity of P-3l
Mu

Mu

pKi +/- SEM

Ki (nM) +/- SEM

P-3l

7.6700.0993

21.362.85

Naloxone
HCl

8.7480.0995

1.787.0239

Compound

150

P -3 I

% B in d in g

C o n tro l
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50
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-1 4

-1 2
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lo g [ H L -0 1 0 ] M

IC50

P-3I
4.272e-008

Control
3.574e-009

Ki

P-3I
2.136e-008

Control
1.787e-009
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-4

-2

[35S]GTP[γS] Opioid Functional Assessment for P-3l
Delta
Type

Compound

Kappa

Mu

Type

Type

EC50 (nM)

EC50 (nM)

EC50 (nM)

Full

367.0 

Full

80.88 

Full

Agonist

66.9

Agonist

8.03

Agonist

P-3l

2.526 
Control

DPDPE

25.62 
U69,693

0.427

210.7  36.5

DAMGO 7.204  1.21

4.12

G T P  S D e lt a A g o n is t F u n c t io n a l A s s a y
80

P e rc e n t O v e r B a s a l

C om pound
C o n tro l

60

40

20

0
-1 2

-1 0

-8

-6

-4

-2

-2 0

L o g C o n c e n t r a t io n ( M )

LogEC50
EC50

-6.435
3.670e-007
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-8.598
2.526e-009

G T P  S K a p p a A g o n is t F u n c t io n a l A s s a y
200

P e rc e n t O v e r B a s a l

C om pound
C o n tro l

150

100

50

0
-1 2

-1 0

-8

-6

-4

-5 0

L o g C o n c e n t r a t io n ( M )

LogEC50
EC50

-7.092
8.088e-008

-7.591
2.562e-008

G T P  S M u A g o n is t F u n c t io n a l A s s a y
80

P e rc e n t O v e r B a s a l

C om pound
60

C o n tro l

40
20
0
-2 0

-1 2

-1 0

-8

-6

-4

L o g C o n c e n t r a t io n ( M )
-4 0

LogEC50
EC50

-6.676
2.107e-007
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-8.142
7.204e-009

Binding Affinity of AK-1401
Kappa

Kappa

pKi +/- SEM

Ki (nM) +/- SEM

AK-1401

5.9980.1246

1005169

Naloxone
HCl

8.9640.0905

1.0870.132

Compound

150

A k -1 4 0 1

% B in d in g

C o n tro l
100

50

0
-1 4

-1 2

-1 0

-8

-6

-4

lo g [ H L -0 1 0 ] M

IC50

Ak-1401
2.010e-006

Control
2.131e-009

Ki

Ak-1401
1.005e-006

Control
1.066e-009
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-2

Binding Affinity of AK-1401
Mu

Mu

pKi +/- SEM

Ki (nM) +/- SEM

AK-1401

7.9790.1262

10.491.79

Naloxone
HCl

8.7480.0995

1.787.0239

Compound

150

A k -1 4 0 1

% B in d in g

C o n tro l
100

50

0
-1 4

-1 2

-1 0

-8

lo g [ H L -0 1 0 ] M

IC50

Ak-1401
2.097e-008

Control
2.131e-009

Ki

Ak-1401
1.049e-008

Control
1.066e-009
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-6

-4

[35S]GTP[γS] Opioid Functional Assessment for AK-1401
Delta

Mu
Kappa

Compound

Type

EC50

Type

Type

EC50

EC50 (nM)
(nM)

(nM)
Full

—

AK-1401

—

—

187.5  51.7

—
Agonist

—

Control

—

—

—

DAMGO 7.204  1.21

G T P  S M u A g o n is t F u n c t io n a l A s s a y
80

P e rc e n t O v e r B a s a l

C om pound
C o n tro l

60

40

20

0
-1 2

-1 0

-8

-6

-4

-2 0

L o g C o n c e n t r a t io n ( M )

LogEC50
EC50

-6.727
1.875e-007
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-8.378
4.185e-009

Binding Affinity of AK-1403
Mu

Mu

pKi +/- SEM

Ki (nM) +/- SEM

AK-1403

6.826 0.070

149.4 14.0

Naloxone
HCl

8.718 0.071

1.914 0.182

Compound

Binding Assay - Mu

% of Control

150

AK-1403
Naloxone - Mu

100
50
0
-10

-8

-6

-4

-2

LOG(M)

-50

Ki
IC50

AK-1403
Naloxone - Mu
1.494e-007 1.755e-009
AK-1403
Naloxone - Mu
2.988e-007 3.511e-009

159

[35S]GTP[γS] Opioid Functional Assessment for AK-1403
Delta
Compound

Kappa

Type

Mu

Type
EC50 (nM)

Type
EC50 (nM)

EC50 (nM)

Partial
—

AK-1403

—

—

—

agonist

950.7 458.4

40%
—

Control

—

—

DAMGO 22.71  2.96

—

GTPS Mu Agonist Functional Assay

% over basal

150

AK-1403
DAMGO

100
50
0
-12

-10

-8

-6

-4

-2

Log(M)

-50

EC50

AK-1403
9.507e-007

160

DAMGO
3.963e-008

Binding Affinity of AK-1406
Delta

Delta

pKi +/- SEM

Ki (nM) +/- SEM

AK-1406

6.553 0.137

279.9 51.9

Naloxone
HCl

7.522 0.059

30.03 2.36

Compound

Binding Assay - Delta

% of Control

150

AK-1406
Naloxone - Delta

100
50
0
-10
-50

-8

-6

-4

-2

LOG(M)
AK-1406
Naloxone - Delta
Ki
2.799e-007 3.094e-008
AK-1406
Naloxone - Delta
IC50
5.599e-007 6.188e-008
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Binding Affinity of AK-1406
Kappa

Kappa

pKi +/- SEM

Ki (nM) +/- SEM

AK-1406

6.266 0.086

541.9 62.8

Naloxone
HCl

8.648 0.071

2.249 0.212

Compound

Binding Assay - Kappa

% of Control

150

AK-1406
Naloxone - Kappa

100

50

0
-12

-10

-8

-6

-4

-2

LOG(M)
AK-1406
Naloxone - Kappa
Ki
5.419e-007 2.572e-009
AK-1406
Naloxone - Kappa
IC50
1.084e-006 5.143e-009
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Binding Affinity of AK-1406
Mu

Mu

pKi +/- SEM

Ki (nM) +/- SEM

AK-1406

8.068 0.063

8.553 0.715

Naloxone
HCl

8.718 0.071

1.914 0.182

Compound

Binding Assay - Mu

% of Control

150

AK-1406
Naloxone - Mu

100
50
0
-10

-8

-6

-4

-2

LOG(M)

-50

Ki
IC50

AK-1406
Naloxone - Mu
8.553e-009 1.858e-009
AK-1406
Naloxone - Mu
1.711e-008 3.716e-009
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[35S]GTP[γS] Opioid Functional Assessment for AK-1406
Kappa

Mu

Delta
Compound

Type

Type

EC50

Type

EC50

EC50 (nM)
(nM)
Full

894.5 

Full
—

AK-1406
agonist

(nM)

—
agonist

50.4
1.121 

Control

82.0  7.15

22.71 
—

DPDPE

—

DAMGO

0.093

2.96

GTPS Delta Agonist Functional Assay
200

AK-1406
DPDPE

% over basal

150
100
50
0
-12

-10

-8

-6

-4

-2

Log(M)

-50

EC50

AK-1406
8.946e-007
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DPDPE
1.204e-009

GTPS Mu Agonist Functional Assay

% over basal

200

AK-1406
DAMGO

150
100
50
0
-12

-10

-8

-6

-4

-2

Log(M)

-50

EC50

AK-1406
8.200e-008

165

DAMGO
2.343e-008

Binding Assay Information
Opioid Binding Assays
DOR

KOR

MOR

Assay Buffer:

50 mM Tris-HCl, pH 7.4
Buffer

50 mM Tris-HCl, pH
7.4 Buffer

50 mM Tris-HCl,
pH 7.4 Buffer

Assay Volume:

0.2 mL

0.2 mL

0.2 mL

Radioligand:

Enkephalin(DPDPE),
[Tyrosyl-3,5-3H(N)]

U-69,593,
[Phenyl-3,4-3H]

DAMGO,
[Tyrosyl-3,5-3H(N)]

Radioligand
Manufacture/Cat#:

Perkin Elmer, Cat#
NET922

Perkin Elmer, Cat#
NET952

Perkin Elmer, Cat#
NET902

Radioligand
Concentration (Kd):

1.615 nM

1.197 nM

2.295 nM

Receptor Membrane:

HEKhDOR
P7 1/20/17

HEKhKOR
P10 1/26/17

HEKhMOR
P15 5/3/16

Membrane
Concentration:

7 g/well

3 g/well

25 g/well

Nonspecific Binding
Control (NSB):

DPDPE
(Tocris Bioscience, Cat#
1431)

U69,593

DAMGO
(Tocris Bioscience,
Cat# 1171)

NSB Concentration:

10 M

10 M

10 M

Assay Incubation:

60 min @ room temperature

Filter Plate:
Range of compound
dilutions:

60 min @ room
temperature
UniFilter-96 GF/B,
pre-treated w/0.3%
BSA

60 min @ room
temperature
UniFilter-96 GF/B,
UniFilter-96 GF/B,
pre-treated w/0.3%
pre-treated w/0.3% BSA
BSA
100 M nM – 560
100 M nM – 560 pM 100 M nM – 560 pM
pM

Range of control
dilutions:

3 M – 17 pM

3 M – 17 pM

3 M – 17 pM

Fold increment for
serial dilution:

3-fold

3-fold

3-fold
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I.

Antinociceptive related assays

Number of writhes (%)

Acetic Acid-induced Abdominal Writhing Assay

100
75

*

*

*
*

50

Vehicle 10 mL/kg
P-31 1 mg/kg
P-31 3 mg/kg
P-31 10 mg/kg
Indomethacin 20 mg/kg
Morphine 10 mg/kg

25
0

Effect of P-3l (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice.
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control.
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental
group. * P ≤ 0.05 using ANOVA followed by Dunnet test.

168

Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice.
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control.
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental
group. * P ≤ 0.05 using ANOVA followed by Dunnet test.
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Number of writhes (%)

100

*
75

*
*

*
*

50

Vehicle 10 mL/kg
AK-1402 1 mg/kg
AK-1402 3 mg/kg
AK-1402 10 mg/kg
Indomethacin 20 mg/kg
Morphine 10 mg/kg

25
0

Effect of AK-1402 (1, 3, 10 mg/kg, P.O.) in the number of acetic acid-induced writhes in mice.
Indomethacin (20 mg/kg P.O.) and morphine (10 mg/kg P.O.) were used as positive control.
Vertical bars represent mean ± SEM of cumulated writhing (%) in 30 min for each experimental
group. *P ≤ 0.05 using ANOVA followed by Dunnet test.
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Formalin Assay
150

Licking time (s)
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p.o.

Effect of P-3l (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10 µmoL/kg
P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and second phase
(15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05
(compared with 1st phase control group) and #P ≤ 0.05 (compared with 2nd phase control group)
using ANOVA followed by Dunnet test.
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Effect of AK-1401 (1, 3, 10 mg/kg, P.O.), indomethacin (20 mg/kg, P.O.) and morphine (10
µmoL/kg P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds.
* P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with 2nd phase
control group) using ANOVA followed by Dunnet test.
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Effect of AK-1402 (1, 3, 10 mg/kg P.O.), indomethacin (20 mg/kg P.O.) and morphine (10
µmoL/kg P.O.) on the licking time of formalin test, in mice, during the first (0-5 min) and
second phase (15-30 min). Vertical bars represent mean ± SEM of pain reaction time, in seconds.
* P ≤ 0.05 (compared with 1st phase control group) and #P ≤ 0.05 (compared with 2nd phase
control group) using ANOVA followed by Dunnet test.
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Opioid Antagonism Assay

Licking time (s)
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Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the P-31 10
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group)
and # P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet
test.
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Licking time (s)
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Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-1401 10
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group)
and # P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet
test.
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Licking time (s)
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Effect of pre-treatment with naloxone (3 mg/kg, IP) or saline (10 mL/kg, IP) in the AK-1402 3
mg/kg P.O. analgesic activity in the first phase (0-5 min) of formalin test, in mice. Vertical bars
represent mean ± SEM of pain reaction time, in seconds. * P ≤ 0.05 (compared control group)
and # P ≤ 0.05 (compared with respectively treated group) using ANOVA followed by Dunnet
test.
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Hot Plate Assay
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Effect of P-31 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O.- positive control) on the hot
plate test, in mice (n = 8). The values were expressed as mean ± SEM of the latency to
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way
ANOVA followed by Bonferroni’s post-hoc test.
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Effect of AK-1401 (1, 3, 10 mg/kg, P.O.) or morphine (10 mg/kg, P.O., positive control) on the
hot plate test, in mice (n = 8). The values were expressed as mean ± SEM of the latency to
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way
ANOVA followed by Bonferroni’s post-hoc test.
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Effect of AK-1402 (1, 3, 10 mg/kg P.O.) or morphine (10 mg/kg, P.O., positive control) on the
hot plate test, in mice (n = 8). The values were expressed as mean ± SEM of the latency to
nociceptive behavior, in seconds. *P ≤ 0.05 compared to control group, according to two-way
ANOVA followed by Bonferroni’s post-hoc test.

179

II.

Antidepressant related assays

Forced swimming test
A

B
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The effect of oral administration of vehicle, AK-1401 at 1, 3, 10 mg/kg, positive control
imipramine (IMI) at 15 mg/kg, and vehicle on the swimming time (B) and immobility time (C)
in the forced swimming test. Each column represents the mean ± S.E.M. of 10 animals. *P <
0.05, *P < 0.01 or *P < 0.001 vs vehicle treated group (one way ANOVA followed by Dunnett´s
test).
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Tail suspension test

The effect of oral administration of AK-1401 at the doses of 1, 3, 10 mg/kg and positive control
imipramine (IMI) 15 mg/kg or vehicle on immobility time in the tail suspension test (one-way
ANOVA followed by Dunnett’s test).
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Open Field Test

Open field test results, Freezing time and Total crossing: AK-1401.
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg,
positive control diazepam (DZP) 5 mg/kg, or vehicle in the open field
exploratory assay on freezing time (A), the total crossing (B), number of
rearing events. Each column represents the mean ± S.E.M. of 10 animals.
*P < 0.05 and ***P<0.001 versus vehicle treated group (one way ANOVA
followed by Dunnett´s test).
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Open field test results, Number of rearing and crossing at the center: AK-1401.
The effect of acute oral administration of AK-1401 at 1, 3, 10 mg/kg, positive
control diazepam (DZP) 5 mg/kg, or vehicle in the open field exploratory assay
on freezing time (C) and crossing at the center of the open-field (D). Each
column represents the mean ± S.E.M. of 10 animals. *P < 0.05 and ***P<0.001
versus vehicle treated group (one way ANOVA followed by Dunnett´s test).
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Figure 4. “Salvia_divinorum_-_Herba_de_Maria”
Used under terms of Creative Commons 2017.
o CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=157218

Figure 8. Reprinted by permission from Macmillan Publishers Ltd: Copyright 2002.
Roth, B.L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K.C.; Steinberg, S.; Ernsberger, P.;
Rothman, R.B. 2002. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid
selective agonist. Proceedings of the National Academy of Sciences of the United States of
America. 99(18):11934-11939.
o License Number: 4053681203902.

Figure 13. Reprinted by permission from Springer: Copyright 2003.
Merlin, M.D. 2003. Archaeological Evidence for the Tradition of Psychoactive Plant Use in the
Old World. Economic Botany. 57(3):295-323.
o License Number: 4062980354466.

Figure 14. Public Domain image provided by TeunSpaans. 2017. Opium pod cut to demonstrate
fluid extraction.
o https://upload.wikimedia.org/wikipedia/commons/3/3b/Opium_pod_cut_to_demo
nstrate_fluid_extraction1.jpg

Figure 15. Public Domain image obtained from Drug Enforcement Agency. 2017. Image of
dried opium.
o https://www.dea.gov/pr/multimedia-library/image-gallery/opium/opium3.jpg

Figure 17. Public Domain image provided by Mpv_51. 2017. Bayer Heroin bottle.
o https://upload.wikimedia.org/wikipedia/commons/f/ff/Bayer_Heroin_bottle.jpg
Figure 23. Reprinted by permission from ASPET: Copright 2007.
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.;
Bohn, L.M. 2007. An Opioid Agonist that Does Not Induce μ-Opioid Receptor — Arrestin
Interactions or Receptor Internalization. Molecular Pharmacology. 71(2):549-557.
Figure 24. Reprinted by permission from ASPET: Copright 2007.
Groer, C.E.; Tidgewell, K.; Moyer, R.A.; Harding, W.W.; Rothman, R.B.; Prisinzano, T.E.;
Bohn, L.M. 2007. An Opioid Agonist that Does Not Induce μ-Opioid Receptor — Arrestin
Interactions or Receptor Internalization. Molecular Pharmacology. 71(2):549-557.
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